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TumourRetrospective proteomic studies, including those which aim to elucidate themolecular mechanisms driving can-
cer, require the assembly and characterization of substantial patient tissue cohorts. The difﬁculty of maintaining
and accessing native tissue archives has prompted the development of methods to access archives of formalin-
ﬁxed tissue. Formalin-ﬁxed tissue archives, completewith patientmeta data, have accumulated for decades, pre-
senting an invaluable resource for these retrospective studies. This review presents the current knowledge
concerning formalin-ﬁxed tissue, with descriptions of the mechanisms of formalin ﬁxation, protein extraction,
top-down proteomics, bottom-up proteomics, quantitative proteomics, phospho- and glycoproteomics as well
as imaging mass spectrometry. Particular attention has been given to the inclusion of proteomic investigations
of archived tumour tissue. This article is part of a Special Issue entitled: Medical Proteomics.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cancer represents one of the largest public health problems, with
1.66 million new cases and 580,350 deaths projected in the US for
2013 [1]. Signiﬁcantly, this estimate is close to the leading cause of
death, heart disease, which lead to 597,689 deaths in 2010 in the US
[2]. The signiﬁcant health burden represented by cancer has lead to
the pursuit of a more comprehensive understanding of the changes
driving tumour initiation, progression and metastasis. Proteomics has
leveraged multiple sample preparation, fractionation and MS tech-
niques over the past two decades to gain an understanding of tumor-
speciﬁc changes in protein abundance and modiﬁcation state. Those
studies which seek to identify the underlyingmolecular pathways driv-
ing a speciﬁc tumor naturally require the biological material to be the
tumor tissue [3]. Fortuitously, biomarker studies also beneﬁt from
using tumor tissue in the discovery phase, as the tissue should have
the highest concentration of any tumor-speciﬁc markers [3,4].
Critical to these studies is the availability of tissue archives. Howev-
er, the difﬁculty of standardized sample collection, preservation and
long term storage for native (i.e. non-ﬁxed) tissue also increases the dif-
ﬁculty in procuring large tissue cohorts for retrospective studies [5].
Surgical pathology has for more than a century used ﬁxatives to
preserve tissue and circumvent the aforementioned issues. The goldProteomics.
, University of Adelaide, Gate 8
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offmann).
. This is an open access article understandard method uses formalin-ﬁxation followed by embedding in
parafﬁn wax to produce formalin-ﬁxed parafﬁn-embedded (FFPE)
archived samples. FFPE tissues can be stored for decades or more at
room temperature while retaining cellular morphology, removing
much of the cost and difﬁculty of sample storage. Furthermore, the
ubiquity of formalin as a ﬁxative in pathology has resulted in the accu-
mulation of vast FFPE archives complete with patient meta-data and
clinical data [6–8].
Use of FFPE tissues for proteomics was traditionally thought to be
too problematic, given the presence of formalin-induced protein
cross-links andmodiﬁcations, which create problems for separating, vi-
sualizing and characterizing individual proteins [9]. The observation
that proteins and proteolytic peptides can be released from FFPE tissue
were thus signiﬁcant proteomicmilestones [6,7,9–11]. The sumof these
works has provided the opportunity for numerous groups to procure
large archived tumor cohorts for retrospective proteomic investigations.
The importance of FFPE tissues to current and future retrospective
proteomic studies of human disease, including cancer, prompted the
current review. The aim of this review is to summarize proteomicmeth-
od advancements and applications relevant to FFPE tumour tissue.2. Formalin-ﬁxed parafﬁn-embedded tissue: process and typical uses
Pathology and research institutes routinely create formalin-ﬁxed
tissue blocks for histopathology. Tissues are ﬁrst immersed for 24–48 h
in formalin. The working stock is usually 4% w/v formaldehyde in
water, which is diluted from 40% w/v stock in water, stabilized by 10%
methanol [12]. Following ﬁxation, tissue blocks are de-hydrated using
a dimethyl-benzene (i.e. xylene) and ethanol series and embedded inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ﬁxed parafﬁn-embedded (FFPE) samples.
For histopathology thin sections (4–10 μm)of frozen and FFPE tissue
blocks are mounted onto microscopy slides and differentially stained
(e.g. haematoxylin& eosin) to allow lightmicroscopy-based assessment
of cell and tissue morphology. This assessment allows a pathologist to
determine tumor characteristics such as sub-type, grade and differenti-
ation state. FFPE samples are favored in histopathology for two reasons.
Firstly, the modiﬁcations induced by formalin allow FFPE tissue to
be stored under ambient conditions for decades, removing the need
for labor intensive and costly maintenance of frozen archives of native
tissue [5]. Secondly, formalin-ﬁxation leads to superior preservation of
tissuemorphologywhen compared to alcohol ﬁxation [13]: an observa-
tion that was ﬁrst made by Ferdinand Blum in 1893, who noted that
formalin-ﬁxed tissues exhibited marginal shrinkage and distortion as
well as excellent staining results [12].
Longevity and morphological stability have thus led to the use
of FFPE tissues as a standard preservation method globally. As such,
most standard criteria for pathological diagnosis were established
using FFPE tissue [13,14]. In addition, virtually universal adoption of
formalin-ﬁxation has allowed for the accumulation of vast institutional
FFPE archives over many decades. Crucially, these archives are linked to
clinical patient data, providing an invaluable resource for retrospective
studies of disease [6,7].3. Modiﬁcations induced by formalin-ﬁxation
The typical working concentration of formalin (i.e. 4%w/v formalde-
hyde) would be expected to penetrate at least 20 mm of tissue over a
typical 24 h ﬁxation period [12]. Once the formaldehyde has penetrated
the tissue, it will react with or cross-link nucleic acids and polysaccha-
rides as well as multiple protein amino acid residues including lysine,
arginine, histidine and cysteine [12,15,16].
In terms of speciﬁc reactions with amino acids, the ﬁrst stage
reaction of primary amines in proteinswith the aldehyde group in form-
aldehyde creates a +30 Da hydroxymethyl-methylol adduct (Fig. 1,
reaction [1]). The elimination of water to produce a Schiff base is thenFig. 1. Reactionmechanism for formaldehyde cross-linking of proteins. Reaction [1] creates a hyd
to form a Schiff base and a total+12mass shift. Reaction [3] is a cross-linking reactionwhere n
acid residue results in a methylene bridge. This research was originally published in Journal of
Proteins: REACTIONS WITH MODEL PEPTIDES. Journal of Biological Chemistry. 2004; 279:6235–possible, creating a total mass shift of +12 Da (see Fig. 1 reaction [2])
[15]. In addition to these reactions, the primary amine can react with
hydroxyl groups to create acetals or alternatively with aromatic rings
to create hydroxymethyl groups [17].
In a second reaction stage, cross-links can be generated through
nucleophilic attack on the methylene carbon of the Schiff base by a
nucleophile on another amino acid residue (see Fig. 1 reaction [3]).
The resulting methylene bridge linking two peptide sequences adds a
total of +12 Da [18]. Peptide model research has found that cysteine,
histidine, lysine and arginine form methylol adducts (+30 Da) when
exposed to formaldehyde, both tryptophan and lysine can form Schiff
bases and that intra-peptide cross-links can form between lysine and
histidine as well as lysine and arginine [15]. Subsequent model peptide
observations indicated that short (10 min), as compared to long (48 h),
formaldehyde exposures result in modiﬁcations to lysine, tryptophan
and cysteine [18]. Thesemodelswere later extended to include a bovine
insulin proteinmodel, whichwas used to conﬁrm the existence of intra-
peptide sequence cross-links [16]. Inter-peptide cross-linking reactions
have been more difﬁcult to elucidate, with model peptide studies indi-
cating both low levels of cross-linking aswell as successful cross-linking
of asparagine/glutamine, histidine, tryptophan, tyrosine, arginine and
the amino-N-terminus of peptides to free glycine in the presence of
formaldehyde [15,18]. The production of inter-protein cross-links can
be clearly seen in protein models of formalin-ﬁxation. For example,
Fowler et al. (2008) showed that ribonuclease A treatedwith formalde-
hyde forms multiple aggregates ranging from dimers to hexamers [19].
Although signiﬁcant steps have thus been taken in the investigation of
these cross-links, further work is needed to elucidate the extent of
formaldehyde induced cross-links, particularly in tissue blocks which
represent vastly more complex molecular mixtures than the models
investigated thus far.4. Accessing formalin-ﬁxed tissues using antigen retrieval
Themostwidespread technique for analysis of FFPE tissue is immuno-
histochemistry (IHC), whereby tissue-speciﬁc staining patterns are
produced through immuno-reactivity between an antibody and tissue-roxymethyl-methylol adductwith a+30Damass shift. Reaction [2] is awater elimination
ucleophilic attack on themethylene carbon of the Schiff base by a nucleophile in the amino
Biological Chemistry. Metz et al. Identiﬁcation of Formaldehyde-induced Modiﬁcations in
6243. © the American Society for Biochemistry and Molecular Biology [15].
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labeled secondary antibody or an enzymatic colorimetric reaction
(e.g. peroxidase conversion of diaminobenzidine, DAB) [20]. Multiple
strategies for overcoming the cross-linked nature of FFPE tissues have
been employed for IHC, including proteolytic enzymes, nucleases and
denaturants (for review see [20]). However, it was not until 1991 that
Shi et al. demonstrated superior IHC staining following heat-induced
antigen retrieval (HIAR) of FFPE tissue sections [21]. The basic HIAR
procedure involves immersion of an FFPE section into a suitable buffer
(e.g. typically citrate or tris at variable pH) followed by heating at 90–
120 °C for 10min up to several hours. Typically, higher temperatures re-
quire less time to achieve the same quality IHC result [13]. HIAR is
thought to promote high temperature cleavage of methylene bridges
and protein denaturation which is stabilized by selection of an appro-
priate buffer pH [13,20].
5. Top down proteomics – extraction of intact proteins from
formalin-ﬁxed tissue
In light of the success of HIAR, proteomic methods for FFPE tissue
have split along the familiar lines of the top-down (i.e. intact protein)
and bottom-up (proteolytic peptide) approaches [for proteomics-
speciﬁc reviews see [5,17,22]]. Hara et al. (1993) and Ikeda et al.
(1998) demonstrated the use of HIAR to identify proteins by immuno-
blot [10,23]. A series of subsequent studies expanded the method base
for top-down proteomics by extraction of proteins through boiling FFPE
tissue in tris buffers with or without SDS [6,7,24–43], the use of proprie-
tary kits [26,29,32,38,42,44–58] and development of application-speciﬁc
procedures (e.g. amyloid protein extraction) [24,59].
These studies, the tissue types used, HIAR method employed
and top-down proteomics end use(s) are summarized in Table 1.
Brieﬂy, these include amino acid sequence analysis, 1-D PAGE, western
blot, immunoassays, ELISA, antibody microarrays, protein arrays, two-
dimensional gel electrophoresis (2-DE), SELDI-TOF MS, MALDI-TOF/
TOF MS, MALDI imaging MS, capillary isoelectric focusing (CIEF) and
LC-MS/MS.
6. Application of formalin-ﬁxed extracts to proteomic investigations
of tumors
19 of the 30 studies in Table 1 used tumour tissue as a sample source
for method validation and various applications. Application examples
include the identiﬁcation of diagnostically relevant proteins (e.g. P53,
E-cadherin) from FFPE colorectal cancer tissue using western blot [10].
HER2 was measured in FFPE breast cancer extracts by western blot
and protein microarray as a diagnostic method in Becker et al. [45]
and for elucidation of the relationship between HER2 phosphorylation
status and signaling activity downstream in Wulfkuhle et al. (2012)
[57]. Nirmalan et al. used FFPE renal cell carcinoma extracts for western
blot validation of protein markers (e.g. HSP60, GAPDH) [29]. Annexin I
was detected in FFPE pancreatic ductal adenocarcinoma cases using
western blot and IHC in Gräntzdörffer et al. [32]. Signiﬁcantly, Berg
et al. (2011) were able to use reverse protein microarrays to measure
expression proﬁles for 17 cancer-related signaling proteins, including
the HER family proteins, in FFPE oesophageal adenocarcinoma. Lysates
from 87 patients were printed onto nitrocellulose coated glass slides
followed by immuno-detection. The protein expression proﬁle obtained
for 11 of the 17 signaling proteins allowed deﬁnition of two distinct pa-
tient groups using hierarchical cluster analysis. Fig. 2A and B show per-
centages of cluster 1 (low HER2 family, high phosphorylated-HSP27)
and cluster 2 (high HER2 family, low phosphorylated-HSP27) patients
with positive diagnoses of distant and lymph node metastases. As illus-
trated by the Kaplan-Meier curve in Fig. 2C, cluster 1 patients exhibited
signiﬁcantly better overall survival. These data supported the assign-
ment of phosphorylated HSP27 and HER2 as prognostic factors for
survival [51].7. Gel electrophoresis of proteins extracted from
formalin-ﬁxed tissue
Of particular interest for proteomics application are electrophoretic
fractionations of extracted proteins by 1-D PAGE [10,26,42] and 2-DE
[7,26,35,38,42]. Multiple top-down studies have employed 1-D PAGE
fractionation of FFPE protein extracts (see also Section 9 – PAGE pre-
fractionation for bottom up proteomics studies) [6,30,36,37,39,52,55,
60,61]. When compared to frozen lysate patterns, proteomic studies
have reported both completely different [10,26] and comparable but
not identical FFPE protein band patterns [6,29,37,45,49].
Ikeda et al. (1998) and Bellet et al. (2008) reported non-identical
protein patterns for FFPE compared to frozen tissue. The fractionated
FFPE lysates exhibited less protein bands, lower resolution bands and
differing band intensities, as compared to frozen lysate. This may have
resulted from less than ideal reversal of FFPE cross-links as several re-
ports, including Bellet et al., have presented PAGE gels with darker
staining in the highmolecular weight range, which indicates the persis-
tence of cross-linked protein aggregates [25,26,31,42]. This assertion
was supported by the observation that tryptic digestion of FFPE protein
bands from 1-D and 2-DE gels resulted in the detection of abundant
proteins above and/or below their expected molecular weight. These
effects are indicative of cross-linked protein aggregates and protein
fragmentation (i.e. HIAR, age or protease induced) respectively [see
review by Tanca et al. 2012 [62] as well as [6,29,31]], which leads to
the typical FFPE gel smearing and background [29,31,32,34].
Similarly variable results have been observed for 2-DE experiments
using FFPE protein extracts. The less than ideal extraction conditions
in Bellet et al. (2008) led to FFPE protein 2-DE gels with almost no ob-
servable similarity to those using frozen tissue extract [26]. Davalieva
et al. (2014) reported that FFPE extracts are unsuitable for 2-DE as a re-
sult of reduced mean spot numbers (see Fig. 3) and the low percentage
of matched fresh frozen 2-DE spots as compared to FFPE gels (e.g. range
of 9.6–10.2% for breast tissue) [42]. Conversely, Addis et al. (2009) suc-
cessfully used FFPE sheep skeletal muscle protein to obtain spot pat-
terns which were comparable to frozen tissue, but with fewer overall
spots visualized in the FFPE gel [7]. Ono et al. (2009) and Tanca et al.
(2011) extended the 2-DE approach by applying DIGE [30,35]. Tanca
et al. compared frozen and FFPE skeletal muscle and liver extracts,
and found similar spot patterns, greater total spots for frozen gels
(see Fig. 3) and slightly increased mean spot volumes for the FFPE gels
[35]. The FFPE protein extract showed a depletion of high molecular
weight proteins which, given their size, have a higher chance of cross-
linking. Furthermore, the overlay of the frozen and FFPE channels for
the DIGE gel indicated a depletion of basic proteins and a generalized
acidic shift in the spot trains. It was hypothesized that the increased
number of modiﬁcations and cross-links expected for a protein contain-
ing a larger number of basic residues led to less efﬁcient extraction [35].
8. Factors affecting formalin-ﬁxed protein extraction and equivalence
to frozen native tissue
A selection of studies in Table 1 also reported the similarity of pro-
tein extracts from frozen and FFPE material. The study speciﬁc details
can be found in Supplementary Table 1. For reviews on protein extrac-
tion and solubilization in FFPE tissue see Tanca et al. (2012) [62] and
Shi et al. (2013) [63].
The main observation to be made from the Supplementary Table 1
summary is that extraction efﬁciencies were variable depending on
the study. This is not surprising given the range of formalin-ﬁxation
times used (4 h to 2 weeks) as well as the differences in tissue type,
block age, tissue dimension and antigen retrieval methods.
For example, Ikeda et al. (1998) and Nirmalan et al. (2009) found
that FFPE tissue produced more protein than frozen tissue [10,29], Shi
et al. (2006) reported comparable yields [25] and multiple studies
reported variability for comparisons across replicates [26], tissue types
Table 1
Previous studies that extracted whole proteins from formalin-ﬁxed tissues for top-down proteomics analyses. Year/author, tissue type, tissue preservation details, extraction buffer, heat induced antigen retrieval (HIAR) temperature and conditions,
end use of protein extract and comment are provided. Asterix in Year/Author column indicates a study included in Supplementary Table 1.
Year/Author Tissue type Tissue preservation Extraction buffer(s) Extraction temperature(s)
and time(s)
Protein end use(s) Comment(s)
1998
Ikeda et al.[10]
*
Colorectal cancer, adenomas and normal
mucosa
i) 10% buffered formalin at
4 °C for 24-48 h
ii) Frozen
FFPE buffer: RIPA buffer pH 7.6 (1 M sodium
dihydrogen phosphate, 10 mM disodium hydrogen
phosphate, 154 mM NaCl, 1% TritonX-100, 12 mM
sodium deoxycholate, 0.2% sodium azide, 0.95 mM
ﬂuoride, 2 mM phenylmethylsulfonyl ﬂuoride,
50 mg/mL aprotinin, 50 mM leupeptin) with 0.1% or
2% SDS
Frozen tissue buffer: RIPA buffer (see above) with 0.1%
SDS
FFPE: 0 °C (2 h), or 37 °C
(2 h), or 60 °C (2 h), or
100 °C (20 min) followed by
60 °C (2 h)
Frozen: 0 °C incubation and
15,000 x g centrifugation at
4 °C (20 min)
SDS-PAGE and
western blot
Presentation of a FFPE tissue protein
extraction method for western blot
analyses
2004
Kaplan et al. [59]
Amyloidosis and normal tissues Neutral buffered formalin Concentrated formic acid Room temperature (24 h)
with stirring
SDS-PAGE, western
blot, amino acid
sequence analysis
FFPE tissue formic acid extraction for
immuno and biochemical
characterization of amyloid deposits
2005
Chu et al. [44]
Brain, breast, heart, pancreas, liver, lung,
spleen, lymph node, colon and prostate
i) Formalin
ii) Frozen
Multiple buffers compared:
i) Tissue-PE LB (GenoTech Inc., MO USA),
ii) 1 mM EDTA and 10 mM sodium citrate,
iii) NDME-PE,
iv) NDME-NE and,
v) NDME-U (Bio-Quick Inc., MD, USA)
100 °C at high humidity
(5–30 min) and immediately
cooled to 4 °C
SDS-PAGE, western
blot, reverse-phase
protein array and
SELDI-TOF MS
Results from development of
nondestructive molecule extraction
(NDME) method for frozen and FFPE
tissue sections
2005
Röcken &
Wilhelm [24]
Spleenic & renal (containing amyloid) i) p-formaldehyde, pH 7.4
ii) Bouin (37% formalin, with
picric and acetic acid)
iii) Methanol: chloroform:
acetic acid (6:3:1)
iv) Frozen
50 mM Tris–HCl, 1 mM DTT, pH 7.5, then,
150 mM Tris–HCl, 8 M urea, 2.5% (w/v) SDS, 20% (v/v)
glycerol, 10% (v/v) 2β-mercaptoethanol, 3% (w/v) DTT,
pH 6.8
Homogenized in buffer I for
2 min and incubated in
buffer ii for 20 min at 90 °C
SDS-PAGE and
western blot
Investigation of the effect of ﬁxation
time on amyloid protein extraction for
diagnosis of amyloidosis
2006
Shi et al. [25]
*
Human breast and resected renal carcinoma,
mouse liver
i) 10% neutral buffered
formalin at room
temperature for 24 h
ii) Frozen
i) Ikeda et al. method
ii) Final solution: 20 mM Tris–HCl (pH 7 or 9) with 2%
SDS
Same procedure for frozen
and FFPE
100 °C (20 min) and 60 °C
(2 h)
SDS-PAGE, western
blot, CIEF and nRPLC-
MS/MS
Establishment of HIAR protocol using
Tris–HCl with SDS and application to
both FFPE and frozen tissue
2007
Becker et al. [45]
*
Murine endometrial carcinoma and
squamous cell carcinoma tumor model
Human placenta, colon, breast and gastric
cancers, non-tumorous colon, gastric and
pancreatic
i) 10% neutral buffered
formalin
ii) Frozen
Qproteome FFPE tissue kit (Qiagen, Hilden, Germany) 100 °C (20 min) and 80 °C
(2 h)
SDS-PAGE, western
blot and reverse-
phase protein
microarray
Development of a method for
solubilizing non-degraded, full length
proteins from FFPE and frozen tissues
for western blot and microarray
analyses
2008
Bellet et al. [26]
*
Normal colonic mucosa i) 4% neutral buffered
formaldehyde for 24 h at
room temperature
ii) Frozen in liquid nitrogen
iii) RCL2 overnight at 4 °C
Multiple buffers compared:
i) 50 mM Tris–HCl, pH 7.5, with 7 M urea, 2 M
thiourea, 2% CHAPS, 1% Mega, 0.5% Triton X 100, 1%
OGP and 50 mM DTT
7 M urea, 2 M thiourea, 4% CHAPS and 1 M DTT
50 mM Tris–HCl, pH 7.5, with 150 mM NaCl, 0.5%
Triton X 100 and 0.5% deoxycholate
Qproteome FFPE tissue kit
Buffer i–iii) 4 °C (20 min)
Buffer iv) 100 °C (20 min)
and 80 °C (2 h)
SDS-PAGE, 2-DE,
MALDI-TOF/TOF MS/
MS, western blot,
SELDI
Comparison of protein extracted from
frozen, FFPE and RCL2 ﬁxed tissue
2008
Becker et al. [48]
Human breast cancer Formalin QProteome FFPE tissue kit 100 °C (20 min) and 80 °C
(2 h)
SDS-PAGE, western
blot and protein
lysates microarrays
Assessment of protein extraction from
FFPE tissues treated with various
histological stains
2008
Chung et al. [47]
Human prostate Formalin Multiple buffers/conditions compared:
i) RIPA (1xPBS, 1% NP-40, 0.5% deoxycholate),
ii) T-PER (Pierce Biotech., IL, USA),
iii) Antigen retrieval buffers (pH 6.0 or 9.9, Dako)
Optimized buffer:
1× antigen retrieval buffer (pH 9.9, Dako), 1% NaN3, 1%
SDS, 10% glycerol and protease inhibitor (Roche))
Incubations (±antigen
retrieval pre-treatment):
4 °C (3 h), or 25 °C (3 h), or
37 °C (3 h), or 65 °C (3 h),
Pressure cooker (at 100 °C,
115 °C or 124 °C): 5 min, or
10 min, or 15 min, or
30 min, or 60 min
Optimized condition:
Homogenized in optimized
buffer, 115 °C (15 min) in a
pressure cooker at 10-15 psi
SDS-PAGE, western
blot and reverse-
phase protein array
Development of a reliable HIAR
method with a pressure cooker to
extract protein from FFPE tissue for
molecular proﬁling analyses
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2008
Kroll et al. [46]
Human normal liver and malignant
melanomas
Formalin Qproteome FFPE tissue kit Five min on ice, 100 °C
(20 min) and 80 °C (2 h)
SDS-PAGE and
western blot
Application of protein extraction to
punch biopsies from deﬁned FFPE
cellular material
2009
Addis et al. (a)
[7]
Sheep skeletal muscle i) 10% buffered formalin for
48 h
ii) Frozen at−80 °C
20 mM Tris –HCl, pH 8.8, 2% SDS, 200 mM DTT FFPE: 100 °C (20 min) and
80 °C (2 h) with shaking
Frozen: Mechanical
homogenizer 30 cycles per
second (3 min)
2-DE, western blot,
MALDI-TOF/TOF MS
and LC-MS/MS
2-DE PAGE separation and
identiﬁcation by MS for proteins
extracted from frozen and FFPE tissue
2009
Addis et al. (b)
[6]
*
Sheep skeletal muscle and liver tissue,
Human hyperplastic thyroid
Sheep:
i) 10% buffered formalin for
48 h
ii) Frozen at−80 °C
Human:
i) Formalin
ii) Frozen at−80 °C
i) 20 mM Tris-HCl, pH 8.8, 2% SDS and 200 mM DTT
ii) 20 mM Tris–HCl, pH 7 with 2% SDS
i) 100 °C (20 min) and 80 °C
with agitation (2 h)
ii) 100 °C (20 min) and 60 °C
with no agitation (2 h)
SDS-PAGE, western
blot, protein array,
ELISA andLC-MS/MS
Optimized method for full length
protein extraction from FFPE tissue for
top down proteomics (e.g. gel
fractionation and LC-MS/MS)
2009
Nirmalan et al.
[29]
*
Human renal cell carcinoma and normal
renal cortex
i) 10% neutral buffered
formaldehyde overnight
ii) Frozen in liquid nitrogen
i) Laemmli buffer – 100 mM Tris–HCl, pH 6.8, 2% w/v
SDS, 20% v/v glycerol, 4% v/v β-mercaptoethanol
ii) Qproteome FFPE tissue kit
Frozen: Laemmli buffer at
100 °C (5 min)
FFPE:
i) Laemmli – 105 °C (20 min
ii) Qproteome kit – 100 °C
(20 min) and 80 °C (2 h)
SDS-PAGE, western
blot and SELDI
Development of novel HIAR strategy
with Laemmli buffer and SDS for
intact protein recovery from FFPE
tissue
2009
Ono et al. [30]
Human cervical intraepithelial neoplasia,
normal cervical and squamous cell
carcinoma tissue
10% buffered formaldehyde
for 24–48 h
20 mM Tris–HCl, pH 7, 2% SDS 100 °C (40 min), 60 °C (2 h) 2-DE, LC-MS/MS,
western blotting
Identiﬁcation of regulated proteins
using a combination of 2-DE and LC-
MS/MS identiﬁcation followed by
western validation
2010
Azimzadeh et al.
[31]
Murine (C57BL/6) heart i) 4% buffered formalin for
24 h
ii) Rinsed with ice cold
20 mM KCl, 2 mM K2HPO4,
1 mM EGTA, pH 6.8 to
remove excess blood
i) Wash with 0.5% β-octylglucoside
ii) Laemmli buffer + 2% SDS
iii) Rehydration buffer + 2% CHAPS
iv) Extraction buffer + 0.2% Tween 20
v) RIPA buffer + 2% SDS, 1% NP-40
vi) 20 mM Tris-HCl, pH 8.8, 2% SDS, 1% β-
octylglucoside, 200 mM DTT, 200 mM glycine
100 °C (20 min), 80 °C (2 h)
with shaking
SDS-PAGE, LIEF-2-DE,
IEF-2-DE, MALDI-
TOF/TOF MS, LC-MS/
MS, immunoblot
Comparison of extraction conditions
for gel and gel-free identiﬁcation of
proteins from FFPE tissue
2010
Ergin et al. [49]
*
Murine liver,
Human non-malignant spleen, breast,
duodenum, kidney, pancreas and stomach
i) Frozen in liquid nitrogen
ii) PAXgene ﬁxation for 3 and
24 h
iii) Formalin ﬁxation for 24 h
QProteome FFPE tissue kit Frozen and PAXgene tissue:
On ice (15 min) and 70 °C
with agitation (2 h)
FFPE tissue: 100 °C (20 min)
and 80 °C (2 h)
SDS-PAGE, western
blot, reverse phase
protein microarrays
and MALDI imaging
MS
Comparison of protein extraction from
frozen, PAXgene ﬁxed and FFPE
tissues
2010
Gräntzdörffer
et al. [32]
*
Human pancreatic ductal adenocarcinoma i) 4% buffered p-
formaldehyde for 4–16 h
ii) Frozen in liquid nitrogen
Frozen tissue: 4 M urea, 0.5% SDS, 62.5 mM Tris, pH 6.8
FFPE tissue: Qproteome FFPE tissue kit
Frozen tissue: Homogenized
and left at room temperature
(20 min)
FFPE tissue: 80 °C
(2 h) ± homogenization
SDS-PAGE and
western blot
Comparison of protein extraction from
frozen and FFPE tissue (sections/
cores)
2011
Berg et al. [51]
Human oesophageal adenocarcinoma Formalin EXB Plus (Qiagen, Hilden, Germany) 100 °C (20 min) and 80 °C
(2 h)
Western blot and
reverse phase protein
array
Measurement of expression levels for
17 cancer-related molecules in FFPE
tissues
2011
Donadio et al.
[33]
Human adenoma parathyroid Formalin 20 mM Tris–HCl, 2% SDS, 0.2 M glycine with variable
pH – N
i) pH 4,
ii) pH 6 and,
iii) pH 9
Sonicated 3× for 10 s each in
buffer, 4 °C (1 h) with
agitation, 100 °C (20 min),
60 °C (2 h)
2-DE-LC-MS/MS,
western blot
Identiﬁcation of proteins from FFPE
tissue extracts using gel-based and
gel-free approaches and validation by
western blot
2011
Rodríguez-
Rigueiro et al.
[34]
Human colon carcinoma i) Formalin
ii)−80 °C frozen
i) 30 mM Tris–base, 8 M urea, 2 M thiourea, 4% CHAPS
ii) 200 mM Tris–HCl, pH 6.8, 20% glycerol, 2% SDS
iii) 200 mM Tris–HCl, pH 7.5, 200 mM NaCl, 5% SDS
and 100 mM sodium citrate
Buffers i and ii: Room
temperature for 1 h with
shaking
Buffer iii: 100 °C (20 min)
and 80 °C (2 h)
SDS-PAGE, western
blot and MALDI-TOF/
TOF MS/MS
Method for extracting full length
proteins from FFPE tissue, as
compared to frozen tissue (not
matched)
2011
Tanca et al. [35]
Sheep skeletal muscle and liver i) 10% buffered formalin for
48 h
ii) Frozen
20 mM Tris–HCl, pH 8.8, 2% SDS and 200 mM DTT 100 °C (20 min) and 80 °C
(2 h)
2-DE DIGE, MALDI-
TOF/TOF MS and LC-
MS/MS
Demonstration of 2-DE DIGE
comparing proteins extracted from
frozen and FFPE tissue
(continued on next page)
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Table 1 (continued)
Year/Author Tissue type Tissue preservation Extraction buffer(s) Extraction temperature(s)
and time(s)
Protein end use(s) Comment(s)
2011
Wolff et al. [54]*
Human muscle, Barrett’s, pancreatic, ovarian
and colon carcinoma, mamma carcinomas,
non-tumorous colon, gastric cancer, non-
tumorous stomach tissue and lymph node
Mouse tumour model of epidermoid or non-
small cell lung cancer
Human tissue:
i) 4% neutral buffered
formalin
ii) Frozen
Mouse tissue: 4% (v/v)
neutral buffered formalin for
6, 24, 48 and 144 h
i) EXB buffer (Qiagen)
ii) EXB Plus buffer (Qiagen)
iii) T-Per (Thermo-Fisher, Rockford, USA)
EXB buffers: 100 °C (20 min)
and 80 °C (2 h)
T-Per: Homogenize tissue in
buffer and centrifuge
Western blot Comparison of two different buffer
systems for HIAR extraction of
proteins from over-ﬁxed and archived
FFPE tissue – also frozen tissue
2012
Fowler et al. [37]
*
Murine liver i) 10% formalin at 4 °C for
48 h, or
ii) Frozen in OCT
i) 50 mM Tris–HCl, pH 7 with 2% SDS (Shi et al. 2006)
ii) 100 mM Tris–HCl, pH 8, 100 mM DTT with 4% SDS
(Ostasiewicz et al. 2010)
Homogenization ﬁrst, then
treatments as listed:
Buffer i (FFPE): 100 °C
(30 min) and
80 °C ± 40,000 psi (2 h)
Buffer i (frozen): Ice bath for
2.5 h, or 100 °C (30 min) and
80 °C (2 h)
Buffer ii (FFPE):
95 °C ± 40,000 psi (60 min)
Buffer ii (frozen): 95 °C
(3 min)
SDS-PAGE,LC-MS/MS Proof of concept for two HIAR
protocols ± 40,000 psi of pressure to
increase protein yield from FFPE
tissues
2012
Kojima et al. [55]
*
Murine pancreatic tissue
Human pancreatic cancer
i) Frozen on dry ice
ii) 4% para-formaldehyde in
PBS for 4 h at room
temperature
iii) 10% neutral buffered
formalin overnight
i) M-PER reagent (Thermo-Scientiﬁc)
ii) QProteome FFPE tissue kit
Frozen tissue: M-PER
manufacturer’s instructions
as well as QProteome
conditions
FFPE tissue: QProteome –
100 °C (20 min) and 80 °C
(2 h)
SDS-PAGE,LC-MS/MS Validation of PAGE and LC-MS/MS
approach for FFPE protein extracts and
application to pancreatic ductal
adenocarcinoma
2012
Strathmann et al.
[56]
Human pituitary adenomas Formalin QProteome FFPE tissue kit 100 °C (20 min) and 80 °C
(2 h)
Luminex
immunoassay and
western blot
Development of clinical method for
quantitative immunoassay diagnoses
using FFPE tissue
2012
Tanca et al. [38]
Human gastric cancer and normal gastric
tissue
i) Formalin, or
ii) Bouin (formalin + picric
and acetic acid)
i) QProteome FFPE tissue 2D PAGE kit
ii) 20 mM Tris–HCl, pH 8.8, 2% SDS and 200 mM DTT
100 °C (20 min) and 80 °C
(2 h)
2-DE, SDS-PAGE,
relative quantitation
by LC-MS/MS
Comparison of protein extraction from
Bouin and Formalin ﬁxed tissue using
PAGE as well as qualitative and
quantitative proteomics by LC-MS/MS
2012
Wulfkuhle et al.
[57]
Human breast cancer i) Formalin, or
ii) Frozen
QProteome FFPE tissue kit 100 °C (20 min) and 80 °C
(2 h)
Western blot and
reverse phase protein
micro array
Use of reverse phase protein
microarrays to measure total and
phosphorylated-HER2 and correlate
this with signal pathways in breast
cancer
2013
Pauly et al. [58]
Human healthy and cancerous breast tissue,
mantle cell lymphoma and follicular
lymphoma
10% neutral buffered
formalin for 24 h
QProteome FFPE tissue kit 100 °C (20 min) and 80 °C
(2 h)
Antibody microarray
analysis
Proof of concept for FFPE protein
extraction and use in recombinant
antibody microarrays
2014
Davalieva et al.
[42]
Human breast and prostate tumour i) 10% neutral buffered
formalin for 24 h, or
ii) Snap frozen in liquid
nitrogen
FFPE i: QProteome FFPE tissue kit
FFPE ii: 20 mM Tris, pH 8.8, 2% SDS and 200 mM DTT
(Addis et al. 2009b)
Frozen:
8 M urea, 2 M thiourea, 4%
(w/v) CHAPS and 50 mM DTT
FFPE: 100 °C (20 min) and
80 °C (2 h)
Frozen: On ice (30 min)
SDS-PAGE and2-DE Compared two types of tissue and two
extraction protocols for FFPE and
frozen tissue for application to 2-DE
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Fig. 2. Correlation between clusters of oesophageal adenocarcinoma patients following reverse protein microarray analysis. Cluster 1 – low HER2 family and high phosphorylated HSP27
expression andCluster 2 – highHER2 family and lowphosphorylatedHSP27expression. Panel A shows thedistantmetastasis status (cM) of patients in both clusters and panel B shows the
lymph node metastasis status (pN). As expected, the Kaplan-Meier curve in panel C illustrates the increased overall survival of Cluster 1 patients. Figure re-printed according to Open
Source Creative Commons Attribution (CC BY) license from Berg et al. (2011) [51].
565O.J.R. Gustafsson et al. / Biochimica et Biophysica Acta 1854 (2015) 559–580[6,49,54] and extraction methods [37]. As expected, the use of frozen
tissue results in a higher amount of extractable protein [28,32,37].
The use of HIAR for most protein extractions in FFPE studies, as well
as the clear demonstration of incomplete recovery and incomplete
cross-link reversal bymultiple top-down gel-based studies demand fur-
ther investigation of optimum HIAR methods as well as pre-analytical
factors which impact protein extraction efﬁciency of FFPE tissue prote-
omics [4,63].
With respect to HIAR development it was noteworthy that top-
down studies showing comparable but not identical 1-D PAGE band
patterns used relatively short ﬁxation times (b48 h), for freshly ﬁxed
non-archived samples, several of which were also subsequently treated
with HIAR in buffers containing SDS [6,29,37,45,49,55].Fig. 3. Column graph showing the two-dimensional gel spot numbers observed for frozen
and formalin-ﬁxed tissues in three different publications. Tanca et al. [35] values aremean
values from triplicate experiments. Davalieva et al. [42] FFPE value is the mean from two
different extraction protocols.Pre-analytical factors can include ischemic times, tissue size, ﬁxative
composition and duration as well as FFPE block age [reviewed in
Thompson et al. 2013 [4]]. For example, formalin-ﬁxation may promote
selective depletion of basic proteins [35] and potentially alsomembrane
proteins as a result of HIAR-induced aggregation [29]. Furthermore, in
the case of increasing block age, Fowler et al. (2012) found that for
younger FFPE blocks (30 day vs. 1 year old) there was no signiﬁcant dif-
ference in yield (usingmodiﬁed extraction conditions and as compared
to frozen tissue) [37]. However,Wolff et al. (2011) – see Supplementary
Table 1 – showed that protein yields decreased from 2.88 mg/mL to
1.68 mg/mL (i.e. 42% decrease) when comparing FFPE blocks from
2010 and 1990 respectively [54]. Similarly, Kroll et al. (2008) reported
that signiﬁcant reductions in protein yield were seen for 14 year old
FFPE blocks as compared to blocks ~1 year old [46]. These studies are
in sharp contrast to bottom-upworkwhich foundminimal or no impact
of block age [see Section 9 as well as [14,64–66]]. In terms of ﬁxation
time, Sprung et al. (2009) found that for 1, 2 and 4 days ﬁxation, only
the 4 day ﬁxation negatively impacted the number of identiﬁed protein
groups [64]. Wolff et al. (2011) reported that ﬁxation times of 6, 24, 48
and 144 h led to incremental decreases in protein yield [54]. Finally,
Tanca et al. (2011) demonstrated that increasing ﬁxation times to 192 h
signiﬁcantly impacted themicrograms of protein extracted permilligram
of tissue [36]. Comparison to a FFPE tissue ﬁxed for 5 years in this same
study showed an even more dramatic decrease in protein yield, suggest-
ing continual development of protein cross-links [36].
The lack of consensus regarding methods for FFPE tissue analysis
in top-down proteomics points to a deﬁnitive need for systematic stan-
dardization [4]. This needs to be combinedwith a deeper understanding
of the interplay between formaldehyde induce protein modiﬁcations
and pre-analytical factors such as ﬁxation time and block age so that
protein extraction efﬁciencies across tissue archives can be ensured.
9. Bottom up proteomics – digestion of extracted proteins for
peptide analyses
Detection and sequencing of peptides from FFPE tissue for bottomup
MS/MS analysis has improved signiﬁcantly over the last decade, largely
due to advancements in extraction procedures and instrumentation. The
ability to remove detergents from protein extraction buffers prior to di-
gestion and RP-HPLC-MS/MS has allowed the use of strong solubilizing
agents such as SDS during FFPE tissue processing. The removal of
Table 2
Previous studies that have performed bottom-up mass spectrometry on formalin-ﬁxed tissues. Tissue type, extraction buffer and conditions, analysis method used, number of peptides and proteins identiﬁed, and notes on the study’s ﬁndings.
Year/Author Tissue type Extraction buffer(s) and condition(s) Analysis methods Peptides Proteins Notes
2005
Hood et al. [71]
Benign prostate hyperplasia
(BPH) and prostate cancer
(PCa) tissue regions, FFPE
SubX with a graded ethanol series. LMD. Liquid
Tissue™, 95 °C 1.5 h.
RP-HPLC Ion Trap BPH = 1300
PCa = 2200
BPH = 702
PCa = 1156
~25% identiﬁed by N1 unique peptide
in both extracts
Known PCa markers identiﬁed in tissue extracts.
Quantitative proﬁling using isotope labelling found
markers greater in PCa compared to BPH cells.
2005
Prieto et al. [72]
Colon cancer Liquid Tissue™ RP-HPLC Ion Trap
SELDI TOF
629 ~140 350 proteins identiﬁed in total, including those with
only 1 peptide identiﬁcation. Revealed complex
peptide spectra.
2005
Palmer-Toy et al.
[9]
Canalplasty FFPE
and fresh frozen
Temporal bone FFPE
and fresh frozen
Heptane and methanol.
2% SDS/100 mM ABC/20 mM DTT pH 8.5,
sonication, 70 °C 1 h. IAA, DTT. CaCl2 to 5 mM,
trypsin digestion. Vacuum ﬁltration via a 3 cm3
Oasis MCX column.
RP-HPLC Ion Trap FFPE = 412
Frozen = 266
FFPE = 42
Frozen = 31
Total protein identiﬁcations for FFPE and frozen tissue
were 123 and 94 respectively, including identiﬁcations
with only 1 unique peptide.
20% proteins unique to frozen tissue.
40% protein unique to FFPE.
2005
Crockett et al.
[11]
FFPE SUDHL-4 cells
Fresh SUDHL-4 cells
Xylene with a graded ethanol series. RIPA
buffer.
RP-HPLC Ion Trap FFPE = 133 (n = 10 MS runs)
Fresh = 231 (n = 10 MS runs)
52% of proteins identiﬁed in both fresh and FFPE
tissues. Biggest bias for detection of proteins from
membrane (39%) and nucleus (48%). 61 proteins
identiﬁed exclusively in FFPE, compared to 251 in
fresh.
2006
Shi et al. [25]
Human renal carcinoma,
FFPE and fresh frozen
Octane and methanol. 20 mM Tris HCL pH 9/2%
SDS, 100 °C 20 min, 60 °C 2 h. SDS removal via
dialysis.
CIEF RP-HPLC Ion
Trap
FFPE HIAR 1 = 3336
FFPE HIAR 2 = 4811
Frozen = 3305
FFPE no heat = 1714
FFPE heat induced AR 1 = 1830
FFPE heat induced AR 2 = 1962
Frozen = 1341
FFPE no heat = 962
Compared HIAR of FFPE with no heating and fresh
frozen tissue. Average amount protein extracted from
FFPE = 10.0 mg/ml, fresh control tissue = 11.5 mg/
ml. MS results showed a higher number of proteins
identiﬁed for the FFPE treated with SDS and heat
induced AR, compared to no heat treatment and fresh
tissue.
2007
Jiang et al. [28]
Mouse liver, FFPE and fresh
frozen
Test protocols;
1. 40 mM Tris pH 8.2/6 M guanidine-HCl/
65 mM DTT, centrifugation 25,000×g 1 h.
2. 40 mM Tris pH 8.2/2% SDS, 100 °C 20 min,
60 °C 2 h.
3. 40 mM Tris pH 8.2/6 M guanidine-HCl/
65 mM DTT.
4. 40 mM Tris pH 8.2/6 M guanidine-HCl/
65 mM DTT, 100 °C 30 min.
5. Frozen; 40 mM Tris pH 8.2/6 M guanidine-
HCl/65 mM DTT.
RP-HPLC Ion Trap 1 = 352
2 = 2540
3 = 589
4 = 3005
5 = 3207
1 = 57
2 = 395
3 = 106
4 = 470
5 = 408
Results showed the majority of peptides identiﬁed
from the FFPE tissue extracts were unmodiﬁed, and
the proteome coverage upon MS analysis was not
obviously compromised as compared to the fresh
tissue.
2007
Guo et al. [27]
Glioblastoma FFPE and fresh
frozen
Octane. LMD. 20 mM Tris pH 9/2% SDS, 100 °C
20 min, 60 °C 2 h. Centrifugation 20,000×g.
Dialysed against 100 mM Tris HCL pH 8.2. DTT
and IAA.
Capillary IEF
RP HPLC Ion Trap
FFPE = 14,748
Frozen soluble = 12,517
Frozen pellet = 16,023
FFPE = 2733
Frozen soluble = 2380 Frozen
pellet = 3110
HIAR method for FFPE compared to fresh frozen tissue
prepared as soluble and pelleted fractions. 1882 (83%)
proteins overlapped between the FFPE, fresh soluble
and pelleted fractions. 243 proteins were unique to
FFPE, 443 to the fresh soluble fraction, and 558 to the
fresh pelleted fraction.
2008
Xu et al. [73]
Human liver, FFPE (n = 3) Octane. 20 mM Tris pH9, dialysed against
100 mM Tris HCL pH8.2. Denatured via 8 M
Urea, DTT, IAA. Diluted 100 mM ammonium
acetate.
capillary
isotachophoresis
(CITP)
RP-HPLC Ion Trap
Ave 18,020 (n = 3)
(17,074, 17,547, 19,441)
Average 3287 (n = 3)
(3209, 3302, 3350)
Average of 5.4 peptides per protein identiﬁed per MS
run. Several runs performed for each sample
corresponding to the CITP fractions.
2008
Patel et al. [74]
Head/neck squamous cell
carcinoma;
normal (n = 4), well
differentiated (WD; n = 4),
moderately differentiated
(MD; n = 4), poorly
differentiated
(PD; n = 4), FFPE
SafeClear II. LMD.
Liquid Tissue™, heat 95 °C 1.5 h.
RP-HPLC Ion Trap Averages;
N = 719.3
WD = 1582.8
MD = 1222
PD = 1115
Averages;
N = 147.5
WD = 351.5
MD = 274.5
PD = 244.3
The aim of the study was to gather information on the
nature of the proteins expressed in normal squamous
epithelium and during Head/neck squamous cell
carcinoma progression.
2008
Jain et al. [91]
Oral HPV lesions, HIV
positive (n = 5) and
negative (n = 5), FFPE
Liquid Tissue™, 95 °C 1.5 h
iTRAQ.
RP-HPLC MALDI-
TOF/TOF
iTRAQ
632 114
9 proteins differentially expressed.
2.8% of the peptides identiﬁed had formaldehyde
modiﬁcations. No signiﬁcant bias was detected in
regards to enrichment of proteins from speciﬁc cellular
compartments. Identiﬁed 9 proteins differentially
expressed in oral HPV lesions caused by HIV infection.
Down regulation CK17 conﬁrmed with IHC.
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2008
Nazarian et al.
[75]
Tumour and
adjacentrifugation normal
tissue of pediatric brainstem
gliomas (n = 2), FFPE
Xylene with a graded ethanol series.100 mM
ABC/30% ACN, 95 °C 30 min, 65 °C 3 h.
18O proteolytic labelling.
RP-HPLC Ion Trap
18O proteolytic
labeling
188 total, 54 up-regulated N1.5 fold
(29%) in tumour.
54 proteins up-regulated, 33 exclusive to pediatric
BSG (others reported for supratentorial malignant
gliomas); potential novel biomarkers of the disease.
Up-regulated proteins include the excreted or
membrane-associated proteins α3-collagen type VI
precursor, α1-collagen type VI, a-spectrin, all involved
in extracellular matrix remodelling and tumour
progression.
2009
Negishi et al. [93]
Tumour and
adjacentrifugation normal
tissue of tongue squamous
cell carcinoma (n = 10 ),
FFPE
LMD. Liquid Tissue™, 95 °C 1.5 h. DTT, IAA. RP-HPLC Q-TOF and
targeted MS/MS
25,018 peaks identiﬁed
and quantiﬁed
Of 25,018 peaks, 72 mass peaks were selected for
targeted MS, all with differential T:N expression,
P b 0.001. Found transglutaminase 3 was signiﬁcantly
down-regulated in cancer and correlated with loss of
histological differentiation.
2009
Addis et al. [6]
Sheep skeletal muscle and
liver, FFPE and fresh frozen
Xylene with a graded ethanol series. 20 mM
Tris HCL pH 8.8/2% SDS/200 mM DTT, 100 °C
20 min, 80 °C 2 h. Centrifugation 12,000×g.
1-DE
RP-HPLC Q-TOF
1DE Frozen = 1824
1DE FFPE = 1706
1DE Frozen = 85
1DE FFPE = 66
Average protein yields of 16.3 mg for skeletal muscle
and 86.8 mg for liver, obtained from tissue areas of
~80 mm2 from 10 μg thick tissue slices.
Immunoassays (WB, ELIZA) successfully performed on
FFPE extracts for GAPDH and actin.
2009
Addis et al. [7]
Sheep skeletal muscle and
liver, FFPE and fresh frozen
Xylene with a graded ethanol series. 20 mM
Tris HCL pH 8.8/2% SDS/200 mM DTT, 100 °C
20 min, 80 °C 2 h. Centrifugation 12,000×g.
2D PAGE, MALDI-
TOF and RP-HPLC
Q-TOF
39 proteins from 2D PAGE Detection of up to 250 individual protein spots by 2D
PAGE (300 μg FFPE protein, MS compatible silver
stain).
2009
Ono et al. [30]
Uterine cervix squamous cell
carcinoma (n = 21) and
normal (n = 53), FFPE
Xylene with a graded ethanol series. 20 mM
Tris pH 7/2% SDS, 100 °C 40 min, 60 °C 2 h.
Centrifugation 15,000×g
2D DIGE
RP-HPLC Ion Trap
NA Identiﬁed 728 differentially expressed proteins; 144
up-regulated, 584 down-regulated compared to
normal. 9 proteins selected for analysis by MS. Heat
shock protein 27 identiﬁed and validated as over
expressed by WB and IHC.
2009
Bagley et al. [14]
Uterine mesenchymal
tumours; uterine
leiomyomas (UL) (n = 9),
alveolar soft part sarcoma
(n = 1), FFPE
Octane. 20 mM Tris/2% SDS, 100 °C 20 min,
60 °C 2 h. Dialysed 100 mM Tris HCL pH 8.2.
Denatured with 8 M Urea, DTT, IAA. Diluted
with 100 mM ammonium acetate pH 8.
CITP/RP-HPLC Ion
Trap
1880 common proteins across
samples, 80 unique to the sarc .
Evaluated the effects time storage on FFPE; UL FFPE
from 1990–2002, sarcoma FFPE 1980. Leiomyomas
categorized 3 groups of three cases by archival year;
1990, 1997, 2002. 1990 group had slightly poorer
proteome performance. Important to rule-out
comparison bias due archival time; leiomyomas did
not cluster by year. Actin, desmin, and progesterone
are all common markers for leiomyomas; expression
values were remarkably consistent over the 12 yr
storage time.
2009
Sprung et al. [64]
Colon adenoma, FFPE and
fresh frozen
Sub-X with a graded ethanol series. 100 mM
ABC alone, and1mM EDTA, or 100 mM
pyridoxamine, 80 °C 2 h. Trypsin, sonication,
60 °C 1 h, sonication. TCEP, DTT, IAA, trypsin
again.
RP-HPLC Ion Trap
IEF (IPG strips) and
RP HPLC Ion Trap
Frozen = 2554, FFPE = 2302.
overlap.
Major difference between frozen and FFPE proteomes;
decreased proportion of lysine C-terminal to arginine
C-terminal peptides, this however had little effect on
identiﬁcations. No bias observed in terms of sub-cellular
location. Increased methionine oxidation; 17% at 1 yr,
25% at 10 years. EDTA and pyridoxamine use slightly
decreased proteins identiﬁed. No effect of storage time
on the number of proteins identiﬁed, 1-10 years. Effect
observed if ﬁxation time N4 days, P b 0.001.
2010
Xiao et al. [67]
Nasopharyngeal carcinoma,
WHO type I (n = 10), II
(n = 10), III (n = 10), and
normal (n = 10), FFPE
Octane and methanol. 20 mM Tris/2% SDS,
100 °C 20 min, 60 °C 2 h. Centrifugation
12,000×g. TCA acetone precipitation. iTRAQ.
2D LC MSMS +
iTRAQ;
SCX HPLC-RP HPLC
Q-TOF
8897 peptides 377. 528 unique proteins by iT
label.
Compared FFPE with previously analysed fresh frozen
tissue. Found all 730 proteins in FF dataset. Compared
subcellular localization and molecular function
groups; distribution of proteins similar between FFPE
and FF. Differential expression levels cathepsin D,
keratin 8, SFN, and stathmin 1 consistent with IHC
results from a previous study.
2010
Kawamura et al.
[76]
Lung carcinoma and lymph
node tissue, stage IA and IIIA,
FFPE
Xylene with a graded ethanol series. LMD.
Liquid Tissue™.
RP-HPLC Ion Trap IA = 449
IIIA = 438 (primary) IIIA = 2 LN
mets)
649 total proteins identiﬁed in primary lesions; 238
(36.8%) in both stages, 211 (32.5%) unique IA, 200
unique IIIA (30.7%). 521 proteins characterised in IIIA
primary and metastatic lesions; 288 (55.3%) lung
lesions alone, 83 (15.9%) LN metastasis, 150 (28.8%) in
both. Subset of proteins were veriﬁed by MRM,
described by Nishumura et al. (below).
(continued on next page)
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Table 2 (continued)
Year/Author Tissue type Extraction buffer(s) and condition(s) Analysis methods Peptides Proteins Notes
2010
Nishimura et al.
[94]
Lung carcinoma (n = 13
from prelim study above
Kawamura et.al.) (n = 14
new), FFPE
LMD
Liquid Tissue™ (as per Kawamura et.al. 2010)
MRM analysis
Triple Quad/linear
Ion Trap
Analysed 8 proteins. Performed MRM on subset candidate proteins taken
from prelim study (same candidates used in both).
Also looked at new samples; stage IA patient’s with
poor outcome, stage IIIA patient’s with good outcome.
Results suggested napsin-A and hAG-2 useful for
staging and expression levels related to regional
lymph node metastasis. Observed correlation between
Napsin-A levels in stage IA patients with a better
prognosis. Stage IIIA cases with a good outcome
displayed napsin-A expression levels similar to the
better prognosis stage IA patients.
2010
Azimzadeh et al.
[31]
Mouse heart, FFPE and fresh
frozen
Test Protocols;
1. Laemmli buffer and2% SDS/
20 mM Tris–HCl pH 8.8
2. 9 M Urea/2% CHAPS/50 mM DTT
3. QProteome/0.2% Tween 20
4. RIPA buffer containing 2% SDS and 1% NP40
5. 2% SDS/1% beta-octylglucoside/200 mM DTT/
200 mM glycine/protease inhibitors.
All samples; 100 °C 20 min, 80 °C 2 h shaking.
Centrifugation 14,000×g.
LIEF (capillary IEF)
1-DE
RP-HPLC Ion Trap/
Orbitrap
1312 192 A mix of the non-ionic detergent 1% beta-
octylglucoside plus 2% SDS gave optimal protein
release from FFPE sections. Increasing amounts of SDS
beyond 4% did not enhance the protein yield further.
To determine the integrity and compatibility of FFPE
extracted proteins with MS, 1 DE gels were run
containing the protein extracts, and entire lanes were
excised into 17 slices (protein bands in the range of
10–200 kDa) and digested with trypsin. MS analysis
was then performed.
2010
Ostasiewicz et al.
[65]
SILAC labelled mouse liver,
FFPE, fresh, and fresh frozen
Xylene with a graded ethanol series. LMD or
needle MD. 0.1 M Tris HCl, pH 8.0, 0.1 M DTT,
blender, soniﬁer, SDS to 4%, 99 °C 1 h.
Centrifugation 16,000×g. Detergent depletion
via FASP.
Anion exchange
Phospho – TiO2.
N-Glyco-FASP –
lectins ConA,
WGA, RCA120.
RP-HPLC Ion Trap/
Orbitrap
FFPE = 5203
Frozen = 5426
91% identical between FFPE and Frozen.
Fresh liver, divided 8ths; 4 pieces used for immediate
extraction, 4 formalin ﬁxed. In terms of protein
extraction, 1 mg fresh tissue gave 140 ± 18 μg
protein, FFPE gave 155 ± 16 ug. Digestion efﬁciency of
FFPE boiled in SDS and FASP digested; 60% protein
converted peptides. 59% of identiﬁed peptides had C-
terminal lysine’s in both the fresh and FFPE, showing
an absence large scale lysine modiﬁcation. No
signiﬁcant difference observed in subcellular location.
No storage time effect of FFPE. H&E staining cause little
to no effect. LMD caused no effect. SILAC; no
quantitative changes between proteomes of FFPE and
fresh samples. Phospho-peptides; 7718 identiﬁed
from fresh tissue, 6870 from FFPE. 4121 (62%)
identiﬁed in both, similarly limited overlap of 59%
observed between 2 fresh samples – likely due large
size phospho-proteome. Large numbers of phosphor
sites preserved in FFPE tissues. In terms of glycol
peptides; 1458 observed in FFPE and 1700 fresh, with
an overlap of 77%.
2010
DeSouza et al.
[92]
Malignant endometrial carci-
noma (n = 10) and non-ma-
lignant (n = 15), FFPE and
fresh frozen
LMD. Liquid Tissue™, heated 95 °C 1.5 h.
Carcinoma samples labelled heavy mTRAQ tag.
Normal samples pooled, labelled with a light
mTRAQ tag, used as reference sample.
mTRAQ
SCX (4 fracs)
RP nanoLC-MRM
hybrid quadrupole/
linear-ion-trap
17 main proteins analysed, 13 routinely
detected. Of the 13, 7 N 1 peptide, 6 only
1 peptide identiﬁed.
Initially analysed 40 proteins identiﬁed in a previous
study and few others of interest. Targeted 17 proteins
in the main study; 13 detected across all sample sets.
The 4 undetected proteins are secreted; study was
performed on LMD epithelial cells, these proteins
would typically be in the extracellular matrix and
probably not sampled. 37% peptides originally
targeted for MRM analysis detected, 24% abundant
enough for reliable quantiﬁcation. Analysed
expression of pyruvate kinase isoform M2 (PK-M2)
and polymeric Ig receptor; differential expression
results comparable between FFPE and fresh tissues of
same individuals, matched previously reported results.
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2011
Nirmalan et al.
[68]
Nephrectomy tumour and
normal, FFPE and Fresh
Frozen (n = 4)
Xylene with a graded ethanol series. RapiGest
buffer, 105 °C 30 min, cool, vortex, 70 °C 2 h.
DTT, IAA.
RP-HPLC Q-TOF
SCX and RP-HPLC
Q-TOF
Quant; UPLC
Waters Synapt
HDMS
FFPE = 283
Frozen = 268
1D LC MSMS: For the normal renal tissue, 350 unique
proteins were identiﬁed in FFPE and frozen tissues.
201 were common to both, 82 (23%) were unique to
FFPE, 67 (19%) unique to frozen. Tumour tissue, 281
unique proteins identiﬁed in FFPE and frozen; 159
common both, 76 (27%) unique to FFPE, 46 (16%)
unique to frozen. Subcellular localisation of protein
from FFPE and frozen tissue similar. 2D LC MSMS:
Matched tumour FFPE and frozen tissue identiﬁcations
were 477 and 490 respectively, 234 (50%) proteins
were common to both samples. Matched normal FFPE
and frozen tissue identiﬁcations were 490 and 622
respectively, 305 (50–60%) proteins were common to
both samples. Concluded to use only 1D LC
fractionation at this stage.
2011
Guzel et al. [96]
Pre-eclamptic placental
tissue and control (n = 5),
FFPE
Xylene with a graded ethanol series. LMD.
Liquid Tissue, 95 °C 1.5 h.
RP-HPLC Ion Trap
MRM Q-Trap
Calcyclin levels signiﬁcantly
(P = 0.0171) higher in trophobl t cells
of pre-eclampsia patients compa d to
controls.
Previously shown placental calcyclin (S100A6)
expression signiﬁcantly higher in early onset pre-
eclampsia compared to controls. Used MRM to
quantify the results.
2011
Tanca et al. [35]
Sheep skeletal muscle and
liver, FFPE and fresh frozen
Xylene with a graded ethanol series. 20 mM
Tris HCL pH 8.8/2% SDS/200 mM DTT, 100 °C
20 min, 80 °C 2 h. Centrifugation 12,000×g.
Precipitated via 2D Clean Up Kit. Resuspended
and DIGE labelled.
2D DIGE
MALDI-TOF or RP-
HPLC Q-TOF
MS performed to identify protein of
different abundance in FFPE vs fr zen
tissue.
2D DIGE FFPE; 315 protein spots observed in skeletal
muscle, 470 spots for liver. Fresh frozen; 592 protein
spots observed in skeletal muscle, 681 spots for liver.
Depleted or absent proteins in the FFPE 2D gels mostly
medium to high MW proteins; likely due to the higher
number of amino acid residues in a protein, resulting
in a higher probability of crosslinking with other
proteins and cellular components, making extraction
from the ﬁxed matrix more difﬁcult.
2011
Byrum et al. [52]
Melanoma melanocytic
nevus (n = 1), metastatic
melanoma (n = 1), FFPE
LMD, Liquid Tissue™. 1DE, band excision,
trypsin digestion.
1-DE
RP-HPLC Ion Trap
88,180 spectra 888; 390 differentially expressed 888 IDs; 390 differentially expressed between
metastatic and nevus lesions. Validated proteins SILV
and FASN as up-regulated in melanoma via IHC.
2011
Tanca et al. [36]
Dog liver, FFPE. Fixation
times; 24, 48, 120, 192 h.
Xylene with a graded ethanol series. 20% w/v
ratio 20 mM Tris HCl pH8.8/2% SDS/200 mM
DTT, 100 °C 20 min, 80 °C 2 h. Centrifugation
12,000×g.
1-DE
RP-HPLC Q-TOF
Proteins extracted with satisfactory yields from tissues
ﬁxed for up to 8 days. Negative correlation between
extraction efﬁciency and ﬁxation time observed;
protein yields from the samples treated for 24 h and
192 h differed signiﬁcantly. All quantitative
parameters showed a negative correlation with
ﬁxation time (r ranging from−0.90 to−0.99)
(including unique protein identiﬁcations, SDS PAGE
proteins extracted, protein scores, mean spectral
counts, MQR, mean pI).
2011
Tanca et al. [60]
Lung neuroendocrine
tumours; typical carcinoid
(TC, n = 3), small cell lung
carcinoma (SCLC, n = 3),
FFPE
Xylene with a graded ethanol series. 20% w/v
ratio 20 mM Tris HCl pH8.8/2% SDS/200 mM
DTT, 100 °C 20 min, 80 °C 2 h. Centrifugation
12,000×g.
1-DE
RP-HPLC Q-TOF
TC = 330 unique
SCLC = 336 unique
461 total unique identiﬁcations.
A mean of 182 unique proteins detected per sample,
4400 mean spectral counts. Samples run on a 1DE
stained CB gel in duplicate. From one duplicate lane
only visible bands excised and subjected to LC MSMS,
from the other duplicate sample the entire lane was
excised and subjected LC MSMS. Signiﬁcantly more
unique proteins were identiﬁed and spectral counts
acquired from the samples analysed from the whole
lanes. 28 differentially expressed proteins detected,
expression of chromogranin-A (Nin TCs) and stathmin
(Nin SCLCs) conﬁrmed by IHC.
2011
Wisniewski et al.
[80]
Colon cancer and matched
normal (n = 3), FFPE
0.1 M Tris-HCl pH 8.0/0.1 M DTT/0.5% (w/v)
PEG
20,000/4% SDS at 99 °C 1 h.
FASP.
SAX
RP-HPLC Ion Trap/
Orbitrap
Cancer = 39,953 ± 1060
Normal = 38,677 ± 1305
(from 6 SAX fractions)
Cancer = 5985 ± 54
Normal = 5868 ± 110
(from 6 SAX fractions)
Technique veriﬁed by detection of differential
expression of 30 known colon cancer markers (e.g.
CEA, DAF, CD55, MACC1); abundance of 26 of the 30
proteins changed in the cancer specimens according to
previously observed over- or under-expression
patterns.
(continued on next page)
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Table 2 (continued)
Year/Author Tissue type Extraction buffer(s) and condition(s) Analysis methods Peptides Proteins Notes
2011
Alkhas et al. [81]
Endometrial cancer,
malignant areas compared to
stromal areas, FFPE
Xylene with a graded ethanol series. LMD.
100 mM ABC/20% ACN, 95 °C 1 h, 65 °C 2 h.
RP-HPLC Ion Trap/
Orbitrap
100 ng digested peptides/
nL tissue, ∼25 pg
peptides/cell. ~3774 total
peptides per run.
Average 1500 proteins ID per run. Characterised peptide recovery from various volumes
of FFPE tissue gathered by LMD. Observed
approximately linear increase in peptide yields with
larger dissected tissue volumes. No discernible
difference in yields extracted from stromal versus
malignant epithelium. Impact of total peptide load on
column; total number peptides/proteins identiﬁed
increased up to loading 1000 ng. Day to day
reproducibility of the extraction method and LC MS/
MS was good.
2011
Bell et al. [50]
Nonalcoholic steatohepatitis,
FFPE and fresh frozen
Liquid Tissue™, heated 95 °C 1.5 h. RP-HPLC Ion Trap 860 total, 225 common between FFPE
and frozen, 142 unique FFPE, 493
unique to frozen.
Frozen = 718 total
FFPE = 367 total (51% of frozen)
A non-speciﬁc decrease in the number of identiﬁed
proteins in the FFPE tissue compared to the frozen
tissue was observed by functional analyses. The overall
relative abundance of a number of proteins involved in
NASH were found to be similar in the FFPE and frozen
liver tissues.
2011
Bateman et al.
[77]
Breast cancer; Stage 0
(n = 7), stage II (2 y
recurrence (n = 5) and non-
recurrence (n = 4)), stage III
(n = 9), FFPE
LMD on min. 30,000 epithelial cells. Liquid
Tissue™.
RP-HPLC Ion Trap 115,549 total 9437 total (n = 25, 3 replicate
injections of each san mple)
Comparing peptides identiﬁed between replicate
injections for all 25 samples revealed average relative
standard deviation of 9.5% ±3.9% in terms of
reproducibility. Analysis stage 0 and stage III patients
revealed 113 proteins that signiﬁcantly differentiated
in expression. Comparison stage II disease with
recurrence vs no recurrence 2 years post diagnosis; 42
proteins signiﬁcantly differed in abundance. Increase
in TSP-1 abundance and loss PARK7 abundance in
stage III and stage II patients with recurrence veriﬁed
by IHC.
2011
Gamez-Pozo et al.
[53]
Non-small cell lung tumors
(NSCLC) FFPE and fresh
frozen, renal cell carcinomas
(RCC), FFPE
Test Protocols;
1. 2% SDS/40 mM Tris–HCl pH 8.2
2. 6 M GdnHCL/40 mM Tris–HCl pH 8.2
3. 30% ACN/100 mM ABC
4. FFPE PES™
5. QProteome™
Protocols 1/2/3; 100 °C 20 min, 80 °C 2 h
shaking.
Phospho-peptide
enrichment IMAC
RP-HPLC Ion Trap/
Orbitrap
NSCLC frozen = 457
NSCLC FFPE = 393
RCC FFPE = 336
NSCLC frozen = 166
NSCLC FFPE = 151
RCC FFPE = 154
Phospho-proteins
NSCLC frozen = 56
NSCLC FFPE = 49
RCC FFPE = 42
Phosphopeptide enrichment to evaluate the
applicability of phosphoproteomic analyses to FFPE
samples. Found SDS-based buffer yielded the highest
amount of protein from FFPE tissues after AR. Between
the FFPE vs frozen tissues no signiﬁcant differences
were observed in the % of uniquely phosphorylated
peptides and proteins.
2011
Donadio et al.
[33]
Adenoma parathyroid
(n = 5) from sporadic
primary
hyperparathyroidism
(PHPT) patients, FFPE
Xylene with a graded ethanol series. 2% SDS/
20 mM Tris–HCl (pH 4, 6, and 9)/0.2 M glycine,
4 °C 1 h, 100 °C 20 min, 60 °C 2 h.
Centrifugation 13,000×g. SDS precipitation.
RP-HPLC Ion Trap/
Orbitrap
163
2012
Jain et al. [97]
Rat spinal cords, healthy and
experimental autoimmune
encephalomyelitis (EAE).
FFPE and Fresh frozen.
Xylene with 70% ethanol. Needle dissection
FFPE tissue.
Liquid Tissue™. iTRAQ.
iTRAQ
LC-MALDI-TOF/TOF
FFPE = 1155
Frozen = 2187
FFPE = 262 unique proteins
Frozen = 500
EAE-induced proteomic changes in FFPE tissues
positively correlated with frozen tissues, but
with ∼ 50% less proteome coverage (result may be
inﬂuenced by use of MALDI MS). 201 proteins found
both FFPE and frozen. The difference in the number of
proteins identiﬁed from FFPE to fresh tissues was
largely caused by lower sample quantities (12 μg/
animal) analyzed from FFPE compared to those from
fresh frozen tissues (90 μg). Captured same
quantitative proteomic differences between EAE and
controls found in frozen and FFPE tissues.
2012
Fowler et al. [37]
Mouse liver, FFPE and fresh
frozen
Xylene with a graded ethanol series. 50 mM
Tris HCL pH 7/2% SDS, sonication, 100 °C
20 min, 80 °C 2 h. 40,000 psi applied using NEP
2320 Barocycler, or kept at atmospheric
pressure.
1-DE
RP-HPLC Ion Trap
Frozen heat = 4581
FFPE N psi = 5192
Overlap = 2318
Extracted FFPE mouse liver with heat, augmented by
elevated hydrostatic pressure.
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2012
Sousa et al. [82]
Intestinall-type gastric
cancer (n = 10), metaplasia
(n = 10), normal mucosa
(n = 10), FFPE
Macrodissection. Sub-X with a graded ethanol
series. 100 mM ABC pH8, 80 °C 2 h,
triﬂuoroethanol, sonnication, 60 °C 1 h,
sonnication. Carboxyethylphosphine, IAA,
trypsin.
Peptide IEF (IPG
strips), RP-HPLC Ion
Trap/Orbitrap
Ave 2350 protein/sample (from 50 μg
total protein).
Overlap of proteins identiﬁed in different tissue
groups N99%, however levels differed (spectral
counts). Detected 60 proteins up regulated and 87
down regulated during progression of normal mucosa
to metaplasia to gastric cancer. Up regulated proteins
predominantly represented by nuclear and membrane
proteins, mitochondrial proteins decreased in
expression. LTF and DMBT1 were validated as markers
for spasmolytic polypeptide– expressing metaplasia
and intestinal metaplasia, respectively. Signiﬁcantly
lower levels DMBT1 or LTF correlated with more
advanced disease and worse prognosis.
2012
Takadate et al.
[83]
Pancreatic cancer, poor
prognosis (n = 4), better
prognosis (n = 4), FFPE
Xylene with a graded ethanol series. LMD.
Liquid Tissue™, 95 °C 1.5 h.
RP-HPLC Ion Trap/
Orbitrap
Total 1099 unique proteins; 845 etter
prognostic, 924 poor prognostic.
6 proteins showed different expression between two
groups. 4 over-expressed in the poor prognostic
group, 2 in the better prognostic group. Conﬁrmed
differential expression of NDPK-A by IHC. Kaplan-
Meier; high Nm23/NDPK-A expression correlated with
signiﬁcantly worse overall survival (P = 0.0103).
Multivariate Cox regression model; independent
predictor of poor survival.
2012
Naidoo et al. [85]
Pancreatic ductal
adenocarcinoma, primary
tumours, matched lymph
nodes (n = 7), FFPE
Xylene with a graded ethanol series. . LMD.
Liquid Tissue™, 95 °C 1.5 h.
MudPIT, RP-HPLC
Ion Trap/Orbitrap
1504 unique proteins (10 μg tiss per
sample); 854 common to all sam les.
115 signiﬁcantly differentially
expressed.
115/854 proteins (13.5%) signiﬁcantly differentially
expressed. 2 proteins conﬁrmed by IHC in 55 cases.
Most if the 854 proteins were cytoplasmic and nuclear
(75.9%), with plasma membrane proteins being less
represented (8.9%). Differential expression of S100P
and 14-3-3Σ between primary tumour and matched
LN conﬁrmed by IHC.
2012
Azimadeh et al.
[61]
Heart tissue (n = 3) of
control and exposed C57BL/6
mice after total body
irradiation using a gamma
ray dose of 3 gray, FFPE.
Xylene with a graded ethanol series. 0.5%
betaoctylglucoside/20 mM Tris–HCl pH 8.8/2%
SDS/1% beta-octylglucoside/200 mM DTT/
200 mM glycine. 100 °C 2 h. Centrifugation
14,000×g. Precipitated, resuspended Tris buffer.
1-DE, RP-HPLC Ion
Trap/Orbitrap
Total 357 Identiﬁed 32 deregulated proteins (P ≤ 0.05) in
irradiated hearts 24 h after the exposure. 32 proteins
signiﬁcantly different between control and irradiated,
with a 1.3 fold expression change. Validated
bioinformatics and immunoblotting. Indicated
radiation induced alterations in 3 main biological
pathways; respiratory chain, lipid metabolism and
pyruvate metabolism.
2012
Sprung et al. [98]
Clear cell renal cell
carcinoma, FFPE and fresh
frozen
Sub-X with a graded ethanol series. 100 mM
ABC pH 8, 80 °C 2 h.
MRM
RP-HPLC Triple
Quad
FFPE = 1982
Frozen = 2154
Targeted a candidate set of 114 peptides; 104
detectable in FFPE and frozen tissues. MRM signal
intensities were on average reduced by 34% in the
FFPE tissue compared to frozen. However, the median
coefﬁcients of variation for measurements in the two
tissue types was highly similar (18–20% CV). MRM
measurements of lysine and arginine C-terminal
peptides from FFPE tissue was reproducible (19.5%
and 18.3% median CV, respectively).
2012
Paulo et al. [86]
Normal pancreas (n = 3),
chronic pancreatitis (n = 3),
pancreatic cancer (n = 3),
FFPE
Heptane and methanol. Centrifugation
20,000×g, dried, resuspended 250 μL 6 M
guanidine-HCl/50 mM ABC/20
mM DTT, pH 8.5, 70 °C for 1 h. IAA, DTT.
RP-HPLC Ion Trap/
Orbitrap
Total 525 (proteins identiﬁed in least
2 of 3 specimens).
78 proteins detected exclusively in the normal tissue
(such as spink1, retinol dehydrogenase, common
pancreatic enzymes), 15 exclusively in the chronic
pancreatitis (such as collagen α1, ﬁlamin A, collagen
α3, and SNC73), 21 exclusively in the cancer (such as
annexin 4A, ﬁbronectin).
2012
Kakimoto et al.
[99]
Colon carcinoma (n = 6),
FFPE
Sections mounted on Indium tin oxide-coated
(ITO) glass slides. Xylene with a graded ethanol
series. 0.1 M AB/30% (v/v) ACN 37 °C 1 h.
Tissue section encircled with paper bond, more
buffer added, covered with coverslip or foil to
keep airtight and pressurised, steamed by
heating 94 °C on hot plate. Trypsin, DHBmatrix.
MALDI-TOF/TOF Pre-treated normal and carcinom
analysed across m/z range 500–4 00. S/
N ratio and average intensity m/ 850
signiﬁcantly higher in cancerous an
normal areas.
Developed a simple in situ pre-treatment technique
for preparing FFPE sections for MALDI-MS. Pre-
treating tissues at a high pressure and temperature for
a short period shown to be sufﬁcient to enhance
permeability but not cause any tissue damage.
Signiﬁcantly increases the signal intensity and S/N
ratio in MALDI-MS analysis of FFPE tissue. m/z 850 ion
identiﬁed as a peptide from Histone 2A.
(continued on next page)
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Table 2 (continued)
Year/Author Tissue type Extraction buffer(s) and condition(s) Analysis methods Peptides Proteins Notes
2012
Kojima et al. [55]
Mouse pancreatic tissues
(n = 8), FFPE and matched
frozen for method developed
Human pancreatic cancer
(n = 11) and uninvolved
tissue (n = 8), FFPE
Xylene with a graded ethanol series.
Qproteome™ FFPE Tissue kit (contains SDS),
100 °C 20 min, 80 °C for 2 h. Centrifugation
14,000×g.
1-DE
RP-HPLC Ion Trap
Mouse FFPE = 958
Mouse Frozen = 1070
630 common peptides
Mouse FFPE = 237
Mouse Frozen = 271,195 common.
Human; Control = 178, cancer = 198.
162 common. 47 proteins signiﬁcantly
increased.
The amount of protein obtained in FFPE tissues
(28 ± 13 ug) was comparable to matched frozen
tissues (30 ± 8 ug). Qproteome FFPE kit contains SDS
which must be removed from the sample prior to LC
MS. 47 potential markers identiﬁed as signiﬁcantly
increased in the human pancreatic FFPE tissues, 28
previously reported.
2012
Gundisch et al.
[87]
Intestine (n = 11) and liver
(n = 17), FFPE and fresh
frozen
Fixation time course; 0, 30, 60, 120, 180,
360 min.
QProteome™.
RP-HPLC Ion Trap/
Orbitrap
Liver = 1254 Aimed to characterize the protein and phospho-
protein ﬂuctuation levels at varying procedural delay
points. Degree of sensitivity of proteins and phospho-
proteins to delayed preservation varied between
different patients and tissue types. General trends of
altered abundance for most proteins was not evident
due to pronounced inter-patient variability. GAPDH
found to be stable.
2013
Takadate et al.
[84]
Pancreatic cancer, poor
prognosis (n = 4), better
prognosis (n = 4), normal
(n = 5), FFPE
Xylene with a graded ethanol series. . LMD.
Liquid Tissue™, 95 °C 1.5 h.
RP-HPLC Ion Trap/
Orbitrap
Poor = 924
Better = 845
Normal = 730
Common all = 503
Common poor/better = 167
Common normal better = 47
Common normal/poor = 50
Label free quantiﬁcation followed by SRM of 170
candidate proteins. 14 proteins overexpressed in
cancerous compared to noncancerous tissue showed
different expression in the poor and better outcome
groups; novel proteins ECH1, OLFM4, STML2
overexpressed in poor prognostic group compared to
the better group, with the documented protein GTR1
expressed reciprocally. High expression levels of the
proteins correlated with signiﬁcantly worse overall
survival (Kaplan–Meier analysis, P b 0.05).
2013
Li et al. [78]
Lung adenocarcinoma
(n = 8), matched normal
(n = 8), FFPE
Xylene with a graded ethanol series. LMD. 8 M
urea/0.4 M ABC/0.1% SDS, 60 °C for 1 h.
120 mM Tris(2-carboxyethyl) phosphine, IAA.
iTRAQ.
iTRAQ
RP-HPLC Ion Trap
1288 210 22 proteins had greater than 1.5 fold differential
expression between tumour and normal tissue.
MUC5B found to be signiﬁcantly increased in
expression in tumour, validated by TMA.
2013
Yoshida et al. [79]
Primary gynaecological
tumour and matched brain
metastases (n = 15), FFPE
Xylene with a graded ethanol series.
Qproteome™ FFPE Tissue kit, 100 °C 20 min,
80 °C for 2 h. Centrifugation 14,000×g.
RP-HPLC Ion Trap 129 total
Primary = 76, 28 unique
Metastatic = 101, 53 unique
Shared = 48
Classiﬁcation of biological processes: The majority of
proteins involved in metabolic processes,
developmental processes, or multicellular organismal
process. Comparison of distribution of proteins
between primary and metastasis; differences in
proteins involved in metabolic, developmental, and
multicellular organismal processes. 3 proteins
validated by WB; ENO, TPI-1higher endometrial and
ovarian cancers, TAGLN2 lower in metastatic than
primary tumours.
2013
Byrum et al. [39]
Melanoma (n = 61); benign
nevi (n = 25), primary
(n = 12), metastatic
(n = 24), FFPE
Xylene with a graded ethanol series. Needle
dissection. 20 mM Tris pH 7/2% SDS, 90 °C for
1 h. Bioruptor; 5 min, high power, 30 sec on/off
cycle. 65 °C for 4 h.
1-DE
RP HPLC Ion Trap/
Orbitrap
Total 1528. 113 different between
benign nevi and primary, 60 different
between benign nevi and metastatic,
and 21 different between primary and
metastatic (P b 0.01, fold-change N 2).
Of 1528 proteins identiﬁed, 171 varied in abundance
signiﬁcantly between benign nevi, primary, and
metastatic tumour. Hierarchical clustering of all
samples showed proteins with signiﬁcant differential
expression clearly separated the benign nevi, primary
melanoma, and metastatic melanoma tissues.
2013
Maes et al. [40]
Colorectal cancer and paired
normal (n = 3), FFPE
Xylene with a graded ethanol series. 20 mM
TrisHCl pH 8.8/200 mM DTT/2% SDS/1%
protease inhibitor, 98 °C for 20 min, 80 °C for
2 h. Centrifugation 14,000×g. Tandem Mass
Tags (TMT) labelling.
TMT, 1-DE, RP-HPLC
Ion Trap/Orbitrap
1629 713 unique proteins, 471 quantiﬁable. Showed a trend of up-regulation of several proteins in
colon tumors, some with structural functions
(collagen 4 A2, histone H2A), some with functions
related to cancer process.
2013
Wisniewski et al.
[88]
Colon adenoma (n = 4),
FFPE
LMD. 0.1 M Tris–HCl pH 8.0/0.1 M DTT/0.5%
(w/v) PEG 20,000/4 % SDS, 99 °C. MED-FASP.
SAX
RP-HPLC Ion Trap/
Orbitrap
Ave 55,144 unique
peptides per sample (all
SAX fractions combined)
Average 8481 per sample. Extraction followed by MED-FASP digestion resulted
in peptide yields of 56 ± 6.1 ng per 1 nL of FFPE
dissected tissue (total volume corresponded to about
100 μg of fresh tissue). SAX-fractionation (into 6
fractions) resulted in 71% of the peptides being
resolved into a single fraction, 6000–18,000 identiﬁed
peptides per fraction.
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2013
Fu et al. [41]
Human Aorta; unﬁxed
(n = 3), FFPE (15 years
(n = 2)), fresh frozen
(3 months (n = 3), 15 years
(n = 3))
Xylene with a graded ethanol series. 20–60 mg
tissue minced scissors, dounce homogenised
100 mM Tris–HCl pH 8.0/4% SDS/100 mM DTT.
Extraction at RT, heat alone, heat and high
pressure; incubated at 24 °C 1 h 14.7 psi, 95 °C
1 h 14.7 psi, or 95 °C 1 h 40,000 psi using a NEP
2320 Barocycler. Centrifugation 16,000×g.
RP-HPLC Ion Trap/
Orbitrap
Average unﬁxed = 671.3
Average frozen 3 mnth = 564.3
Average frozen 15 y = 48.7
Average FFPE = 577
(Results for heat and pressure
treatment)
Combined heat and elevated pressure increased
protein yield from frozen or FFPE compared with heat
alone (1.5-fold) or at RT (8.3-fold). This resulted in
more identiﬁcations with higher sequence coverage.
Increased storage length adversely affected the quality
of proteins extracted from the frozen tissue. For long-
term storage of aorta tissue, FFPE gives better
preservation.
2013
Wisztorski et al.
[89]
Tubo-ovarian cancer, FFPE Tissue microdigestion on selected tissue region.
Extraction of microdigested region by liquid
microjunction using a solvent.
RP-HPLC Ion Trap/
Orbitrap
Total 3649 Ave 1109, 792 in cancerous region, 983
in benign.
FFPE tissue of salpingo-oophorectomies, all tumors Ki-
67 and p53 mutation positive. Aim to use
microdigestion to study groups of cells (around 2500)
to understand the mechanisms involved in the region
(such as communication or cellular organization). 123
proteins detected as speciﬁc to cancer region, 315 to
the benign region. Revealed known cancer signalling
pathways and biomarkers.
2013
Craven et al. [66]
Normal kidney (n = 16),
clear cell renal cell carcinoma
(n = 8), FFPE archived for
up to 10 years
Xylene with a graded ethanol series. 62.5 mM
Tris–HCl pH 6.8/4% w/v SDS/10% v/v glycerol/
100 mMDTT, 105 °C 45 min. Centrifuged, 95 °C
2 min, FASP digestion.
RP-HPLC Ion Trap/
Orbitrap
Normal = 2663 in total dataset (mean
2121).
Carcinoma = 2516 in total dataset
(mean 1671).
Aim to characterize the effect of storage time on FFPE
tissue blocks in pathology archives on the quality of
data produced using label-free MS. No signiﬁcant
effect caused by FFPE block age. Good overlap in
protein identiﬁcations between FFPE sample types of
different age. Greater biological variability apparent in
renal cell carcinoma, possibly reﬂecting disease
heterogeneity.
2014
Matsukawa et al.
[95]
Oral squamous cell
carcinoma (n = 18), FFPE
Liquid Tissue™ RP-HPLC Triple TOF 70,510 total peaks/sample
detected, quantiﬁed.
10,869 peaks differed
intensity between
resistant and sensitive
groups.
Aim to analyse sensitivity to radio- and chemo-
therapy. Identiﬁed galectin-7 as a potential predictive
marker chemotherapy and/or radiotherapy resistance;
sensitivity 96%, speciﬁcity 39.5% (IHC validation,
n = 68). Cumulative 5-year disease-speciﬁc survival
rate was 75.2% in patients with resistant prediction,
100% in patients with sensitive prediction.
2014
Hammer et al.
[43]
Wilms’ tumour. FFPE and
fresh frozen
Wilms’ tumour and normal
renal tissue (n = 7), FFPE
Heptane. 2% Tris/2% SDS, 100 °C for 20 min,
80 °C for 2 h. Centrifugation 14,000×g.
Methanol-chloroform precipitation. 25 mM
ABC, DTT, IAA.
RP-HPLC Ion Trap/
Orbitrap
FFPE tumour vs
normal = 2353 IDs
(found in all patients).
FF normal = 743
FFPE normal = 1168
FFPE tumour vs normal = 879 (found
all patients)
FFPE vs frozen tissue for matched Wilms’ tumour
revealed 65% overlap in protein identiﬁcations.
Comparison of FFPE tissues of Wilms’ tumour vs
normal renal tissue found 262 differentially expressed
proteins, with 30% having higher expression in the
tumour. Expression of Col1A1, TGF-β1, Lasp 1, ezrin,
and NH-ERF1 validated by IHC. Replicate
measurements for fresh frozen tissue from single
patients revealed 34% variability in each protein set.
Total number of proteins identiﬁed ~20% higher in
frozen samples compared to FFPE samples; differences
between the proteome patterns of healthy frozen and
FFPE tissues 34% – this is in range of technical and
biological replicates.
2014
Bronsert et al.
[90]
Tumour tissues; lung cancer
(n = 2), squamous cell
carcinoma (n = 1), hepatic
metastasized colorectal
cancer (n = 3)
FFPE treated 3 different
extraction methods;
microwave, ethanol and
vacuum ﬁltration
Medite Tissue Strainer COT 20, Xylene with a
graded ethanol series. 100 mM HEPES pH 7.5/4
% (w/v) SDS/50 mM DTT, 95 °C 1 h.
Centrifugation 14,000 rpm. Acetone
precipitation. 100 mM NaOH pH 8. Trypsin,
DTT, IAA.
RP-HPLC Ion Trap/
Orbitrap
3850–4210 peptides on
average.
765–1003 proteins Processed tumour tissue samples with microwave,
vacuum/ethanol, and a xylene based systems, and also
cryopreservation. The different extraction methods
yielded comparable numbers of peptide identiﬁcations
for the 3 different processes. Between 3850 and 4210
peptides identiﬁed on average, correlating to 765–
1003 proteins. 4390 peptides identiﬁed in the
cryopreserved sample. Different processing methods
resulted in similar representation of protein sub-sets
in terms cellular localization and molecular function,
comparable yields in terms relative protein
abundances.
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of ways; vacuum ﬁltration [9], dialysis [14,27], precipitation [67],
RapiGest™ fromWaters, an acid cleavable detergent [68], and the FASP
methoddevelopedbyWisniewski et al. (2009) [65,69]. A number of stud-
ies have employed 1-DE as a pre-fractionation step prior to LC-MS/MS
analysis, exploiting the solubilizing capabilities of SDS and its ease of re-
moval during in-gel protein digestion [6,31,36,37,39,40,52,55,60,61].
The combined use of SDS and pre-fractionation by 1-DE can signiﬁcantly
improve the number of peptide identiﬁcations by enhancing protein ex-
traction and reducing the complexity of protein samples prior toMS anal-
ysis, increasing the probability of detecting low-copy-number proteins.
Tanca et al. (2011) found excising, segmenting, digesting, and subjecting
whole 1-DE sample lanes to LC- MS/MS (even in the absence of visible
protein staining) signiﬁcantly improved the number of proteins identi-
ﬁed from FFPE tissues.
The FASP method developed by Wisniewski et al. (2009) has
allowed for the use and easy removal of SDS in FFPE protein extraction
buffers with minimal sample loss. Tanca et al. (2014) compared the
FASPmethodwith direct trypsinisation and protein extraction followed
by in solution digestion. For direct trypsinisation of FFPE tissue, samples
were homogenised in ABC, reduced, alkylated, and digested with tryp-
sin. Samples subjected to protein extraction were treated with SDS
buffer and heated to 99 °C, followed by centrifugation and detergent
removal by spin columns. Direct trypsinisation showed the best preser-
vation of high MW proteins, whilst the FASP and in solution digestion
methods produced higher yields of hydrophobic and membrane
proteins. The FASP method produced the highest number of peptide
identiﬁcations, 4623, at a reproducibility of 44.1%, compared to direct
trypsinisation with 2895, at a reproducibility of 32.6%, and in solution
digestion with 2798, at a reproducibility of 56.5% (n= 3). This resulted
in 1353 protein identiﬁcations for the FASPmethod (65.2% reproducibil-
ity), followed by direct trypsinisation at 1126 (58% reproducibility), and
in solution digestion at 1124 (69.5% reproducibility) (n = 3) [70].
In terms of successful bottom-up analysis, long archival periods of
FFPE tissue blocks appear to have little to no effect on MS results [14,
64–66]. Sprung et al. (2009) observed no major difference in terms of
protein identiﬁcations from FFPE tissue stored for up to 10 years, with
the only discernable difference between fresh frozen and FFPE tissues
being a decreased proportion of C-terminal lysine to C-terminal arginine
peptides in the FFPE samples. This however, had little effect on protein
identiﬁcations. Conversely Fu et al. (2013) found long term storage of
cryo-preserved samples adversely affected the quality of proteins
extracted from the tissue, concluding FFPE was a favorable option for
long-term preservation.
Initially, the most common instrumentation used for bottom-up se-
quencing of FFPE tissues was Ion Traps given their availability and high
levels of sensitivity for protein identiﬁcation analysis. Of the 59 papers
summarized in Table 2, 21 used standalone Ion Traps for peptide
sequencing and protein identiﬁcation [9,11,14,25,27,28,30,37,50,52,55,
64,71–79]. From these papers (excluding those that used a pre-
fractionation step), the average number of unique protein identiﬁca-
tions was 274 ± 222. In more recent times standalone Ion Traps have
been replaced with more advanced instrumentation such as Ion Trap/
Orbitrap hybrids, combining the sensitivity of the Ion Trap with the
high resolution and mass accuracy of the Orbitrap, as seen in 20 papers
since 2010, summarized in Table 2 [31,33,39–41,43,53,61,65,66,80–90].
The average number of unique protein identiﬁcations from studies
using Ion Trap/Orbitrap hybrid instruments as listed in Table 2 is
996± 656 (excluding those that used a pre-fractionation step), indicat-
ing amarked improvement in proteome coverage as compared to using
RP HPLC Ion Trap MS alone. In 2010 Ostasiewicz et al. used a hybrid Ion
Trap/Orbitrap instrument to compare SILAC labeled mouse liver that
had been processed fresh and had also been formalin-ﬁxed. Little differ-
ence was seen between the fresh and FFPE processed tissues, with 5426
and 5203 unique protein identiﬁcations respectively pertaining to a 91%
overlap in proteome coverage (see Fig. 4). Technological advances haveallowed for such increases in proteome coverage for traditionally difﬁ-
cult samples such as FFPE tissues. Not surprisingly, the use of a pre-
fractionation step such as 1-DE, IEF, CITP, SCX, CIEF, or MudPIT, prior
to LC-MS/MS improves the number of protein identiﬁcations achieved
further (average 2462 ± 2279, as listed in Table 2), despite the type of
mass spectrometer used for analysis [14,25,27,31,36,37,39,40,52,55,61,
64,65,73,80,82,85,88].
10. Application of label-free proteomics in formalin-ﬁxed
tumour research
A number of studies have successfully performed label-based [67,75,
78,91,92] and label-free [36,39,43,52,60,61,76,79,82–86,89,93–95] MS
quantiﬁcation of FFPE tissue. Nazarian et al. (2008) used 18O proteolytic
labelling to analyse paediatric brainstem gliomas and found 54 up-
regulated, 33 of which were exclusive to the disease (the remaining
21 proteins had been previously reported in supratentorial malignant
gliomas). Up-regulated proteins of interest included α3-collagen type
VI precursor, α1-collagen type VI, and a-spectrin, all excreted or
membrane-associated proteins involved in extracellular matrix remod-
elling and tumour progression. Negishi et al. (2009) found the signiﬁ-
cant down-regulation of transglutaminase 3 in tongue squamous cell
carcinomaby label free quantitation and observed the change in expres-
sion correlated with loss of histological differentiation. Sousa et al.
(2012) identiﬁed potential markers of spasmolytic polypeptide–ex-
pressing metaplasia and intestinal metaplasia, LTF and DMBT1, respec-
tively. Signiﬁcantly lower levels of the proteins correlated with worse
prognosis and advanced disease. Pancreatic cancer studies by Takadate
et al. (2012) also identiﬁed potential prognostic markers using label-
free analyses. High levels of the protein Nm23/NDPK-A were found to
correlate with signiﬁcantly worse overall survival (P = 0.0103) and a
multivariate Cox regressionmodel showed the protein to be an indepen-
dent predictor of poor survival. A second study found the novel proteins
ECH1, OLFM4, STML2 to be overexpressed in patients with poor progno-
sis and Kaplan–Meier analysis showed high expression levels correlated
with signiﬁcantly worse overall survival (P b 0.05). Furthermore, Naidoo
et al. (2012) discovered a set of epithelial-speciﬁc therapeutic targets in
pancreatic ductal adenocarcinoma (PDAC) by comparing primary tu-
mours and lymph node metastases using MudPIT label free analysis
[85]. 1504 unique proteins were identiﬁed from 10 μg tissue per sample
and 115 were found to be signiﬁcantly differentially expressed. Fig. 5
shows the IHC validation for these label free results. Fig. 5A, D and G
feature IHC for primary PDAC and 5B, 5E and 5H feature IHC for lymph
node metastases against S100P, 14-3-3 Sigma and Moesin, respectively.
Fig. 5C, F and I highlight the median IHC scores and their associated
inter-quartile ranges to demonstrate IHC validation for proteins with a
high (S100P), medium (14-3-3 Sigma) and low (Moesin) g-test score.
S100P and 14-3-3 were found to be signiﬁcantly increased in malignant
epithelia [85].
A number of additional disease markers have been identiﬁed using
quantitative MS on FFPE tissues, as not all of them can be discussed
here a very brief description of some of the interesting ﬁndings is
given in Table 2. The results from quantitativeMS studies on FFPE tissue
have been veriﬁed in a number of studies by techniques such aswestern
blotting and immunohistochemistry, conﬁrming the robustness of the
technique for FFPE tissue analysis [6,7,43,52,60,67,79,83,85,91,95].
11. Post-translational modiﬁcations in formalin-ﬁxed tissue
Recently, efforts have been made to extract and analyze proteins
with post-translational modiﬁcations (PTMs) from FFPE tissue. Blotting
against phosphorylated proteins has been performed using FFPE ex-
tracts [46,49,87]. However, global analysis of preserved phospho and
glyco-proteinmodiﬁcations in FFPEmaterial has only been demonstrat-
ed a handful of times. Seminal work on protein glycosylation in FFPE
Fig. 4. Comparison of ﬁlter aided sample preparation (FASP) protocol for FFPE and frozen liver tissue. (Ostasiewicz 2010). Panel A and B show the protein yield in μg/mg and peptide yield
percentage respectively. Panel C shows a coomassie stained SDS-PAGE comparison of the protein extracts. Panel D shows the overlap of protein identiﬁcations from fresh frozen and FFPE
tissue. Panel E shows the frequency distribution for amino acids from the identiﬁed proteins across FFPE and frozen tissue and panel F highlights their sub-cellular localization. Note that all
the analyses indicate a high degree of similarity. Reprinted with permission from Ostasiewicz et al. Copyright 2010 American Chemical Society [65].
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sites [100].
Subsequently, Ostasiewicz et.al improved upon this study by apply-
ing FASP, PTM-speciﬁc enrichment strategies (e.g. TiO2 and lectin afﬁn-
ity) and LC-MS/MS to murine liver tissue. Initially, frozen and FFPE liver
were compared to show the absence of any bias in protein yield, peptide
yield, PAGE band pattern, frequency distribution of amino acids and
sub-cellular localization of identiﬁed proteins. Following this, liver
from normal and SILAC (L-13C6-Lys) mice were preserved either by
freezing or FFPE. FASP was used to produce normal and SILAC labeled
peptides, which were combined, subjected to PTM enrichment and an-
alyzed by LC-MS/MS.Using this strategy 4991phosphorylation sites and
1458 N-glycosylation sites were characterized in FFPE tissue. Fig. 6A
shows a Venn diagram comparison of N-glycosylation sites identiﬁed
from fresh frozen and FFPE liver tissue. Importantly, quantitative pres-
ervation of phosphorylation and glycosylation was demonstrated by
comparing a 1:1 mixture of fresh frozen and FFPE liver tissue from
normal and SILAC mouse liver [65].
Subsequent work by Gámez-Pozo et al. (2011) using enrich-
ment and LC-MS/MS was able to identify 56 (76 phosphopeptides), 49
(80 phosphopeptides) and 42 (54 phosphopeptides) unique phospho-proteins from shot-gun LC-MS/MS analyses of frozen non-small cell
lung cancer (NSCLC), FFPE NSCLC and FFPE renal cell carcinoma (RCC)
respectively [53]. Importantly, this study demonstrated successful ap-
plication of selected reaction monitoring (SRM) to phosphopeptides
produced from FFPE tissue [53]. Most recently, Wakabayashi et al.
(2014) demonstrated the identiﬁcation of 1413 and 1197 unique
phosphopeptides (overlap of 654) from FFPE and frozen tissue sections
of murine liver (see Fig. 6b) as well as quantitation using Stable Isotope
Dimethyl Labeling [101]. This work was especially signiﬁcant as it re-
quired 3-5 FFPE sections only, in comparison to milligrams of tissue
used previously [65].
Together with the success of quantitative bottom-up analyses of
FFPE tissue, the ability to identify and quantitate PTMs using protein
extracted from FFPE tissue will be invaluable for future retrospective
studies of archived tissues.
12. In situ mass spectrometry – spatial imaging of peptides
In an effort to extend spatial proteomics to archived tissue analyses,
methods have also been developed for FFPE MALDI imaging [102,103].
MALDI imaging encompasses the collection of spatially referenced
Fig. 5. Immuno-histochemistry (IHC) validation of results for MudPIT label free analysis of malignant epithelia and matched lymph node metastases from pancreatic ductal adenocarci-
noma (PDAC). Total validation sets included 52, 51 and 51 samples for S100P, 14-3-3 Sigma and Moesin respectively. Representative IHC scans (100× magniﬁcation) for primary PDAC
against S100P, 14-3-3 Sigma and Moesin appear in panels A, D and G respectively. IHC scans for lymph node metastases against the same three proteins appear in panels B, E and H
respectively. C, F and I show the median IHC score with inter-quartile range (P = 0.05) for the same three proteins respectively. S100P was highly expressed in primary PDAC and
metastases, while 14-3-3 Sigma was only expressed in the malignant epithelium (P b 0.001). Moesin score was not signiﬁcantly changed in IHC analyses. Reprinted with permission
from Naidoo et al. Copyright 2012 JohnWiley and Sons [85].
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(i.e. single spectra from speciﬁc locations) or an imaging mode (i.e. mul-
tiple spectra from a grid across the tissue). MALDI imaging allows collec-
tion of spatial distribution for hundreds ofmolecular featureswithout the
use of antibodies [104]. See the following reviews on imaging MS:
McDonnell et al. (2007) [105], Gustafsson et al. (2011) [106], Schöne
et al. (2013) [107], Gorzolka et al. (2014) [8]]. MALDI imaging data can
also be overlaid with histological stains, providing a method for molecu-
lar histology which is virtually impossible to achieve with the aforemen-
tioned top-down and bottom-up approaches. This capability needs to be
weighed against the reduced analytical sensitivity of MALDI imaging,
which results from the absence of a pre-analytical fractionation step,
as well as the need for technologies such as LC-MS/MS to assist in the
identiﬁcation of analytes of interest.
Seminal work by Lemaire et al. demonstrated that for FFPE tissues
less than a year old, small protein masses (b10 kDa) can be detected
using either sinapinic acid or 2,4-dinitrophenylhydrazine (DNPH)
[102]. This work was extended to include micro-spotter assisted pro-
teolytic digestion with multiple enzymes (e.g. trypsin, V8 protease,
Asp-N and Lys-C) to achieve MALDI imaging of peptides. LC-MS/MS
analysis of extracts and in situMS/MS conﬁrmed the identity of 21 tryp-
tic peptides [102]. The observation that protein signals acquired from
FFPE tissue were less than ideal combined with the marked success ofproteolytic digestion in situ [102,108,109] prompted the coupling of
HIAR methods to proteolytic digestion, predominantly with trypsin
[103,110–112]. Brieﬂy, themethod involves HIAR, deposition of proteo-
lytic enzyme (usually trypsin), an incubation step and ﬁnallymatrix de-
position. For protocols see Casadonte et al. (2011) [113] and Gustafsson
et al. (2013) [114]. Proteolytic peptide MALDI imaging on FFPE tissue
produces highly complex peptide mixtures from cellular proteomes.
As such, multiple studies have concluded that high mass accuracy is re-
quired for subsequent identiﬁcation and validation of tissue-speciﬁc
spatial data [115–117]. This has been achieved either through external
calibration [113], internal calibration [116], or the use of high mass ac-
curacy instruments such as MALDI-Orbitrap [115]. The most signiﬁcant
application for peptide MALDI imaging has been FFPE tissue micro-
array (TMA) projects that highlight molecular differences between
large stratiﬁed patient cohorts [103,118–121].
For example, Groseclose et al. (2008) analyzed 50 duplicate FFPE
cores (total N = 100) from patients with non-small cell lung cancer
(NSCLC). By printing proteolytic enzyme, followed by MALDI matrix, it
was possible to acquire MS spectra containing hundreds of peaks with
S/N N3 [103]. These spectra and a support vector machine (SVM) algo-
rithm were used to produce a classiﬁcation rule which could correctly
classify 97.9% of adenocarcinomas and 98.6% of squamous cell carcino-
mas, as compared to pathologist annotations. Fig. 7 highlights these
Fig. 6. A. Result of ﬁlter aided sample preparation (FASP) protocol and lectin afﬁnity
N-glycopeptide enrichment from Ostasiewicz et al. (2010). Figure shows the overlap of
unique glycosylation sites identiﬁed from FFPE and fresh frozen murine liver tissue.
Reprinted with permission from Ostasiewicz et al. Copyright 2010 American Chemical
Society [65]. B. Overlap of phosphopeptides identiﬁed from FFPE and fresh frozen liver
sections using phase transfer surfactants (PTS) combined with hydroxy acid-modiﬁed
metal oxide chromatography (HAMMOC) phosphopeptide enrichment. Reprinted with
permission fromWakabayashi et al. Copyright 2014 American Chemical Society [101].
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classiﬁcation of both carcinoma types (Fig. 7a–d RIGHT) [103]. Subse-
quent studies, including Quaas et al. and Steurer et al. have extended
this concept from 50 patients to 477 (oesophageal cancer) and 729
(prostate cancer) patient cores respectively, indicating a substantial
increase in cohort size for retrospective FFPE tissue analysis [120,121].Fig. 7. Representative image showing the pathologist classiﬁcation for four formalin-ﬁxed tissuem
(non-small cell lung cancer, NSCLC). Panels a–d (left) show the pathologists annotations (red= c
show the histological class imaging based on MALDI imaging data. Reprinted with permission frThese large MALDI imaging studies are bridging the gap between
pathology and proteomics, and represent a signiﬁcant step forward in
the use of FFPE tissues in retrospective proteomics studies.
13. Conclusions
The growth in FFPE proteomics over the past decade has been driven
by the pursuit of proteome-based information from the vast FFPE
archiveswhich exist around theworld. This is largely a result of the pos-
sibility for combining proteomics with mining of the patient meta-data
associated with the archived samples, which can include disease course
and patient outcome. These kinds of studies would be hugely beneﬁcial
to the ﬁeld, as it would no longer be difﬁcult to assemble large retro-
spective cohorts.
Top-downproteomics on FFPE tissue still requires standardization of
tissue solubilization and HIAR processes to overcome variability in pro-
tein extraction and fractionation results. It will also be crucial to further
develop our understanding of the extent of formalin-induced cross-
links. This understanding will directly impact the future feasibility of
large scale studies of full-length proteins from FFPE tissues, particularly
for cohorts containing older sample blocks, which are harder to retrieve
by HIAR. Bottom-up proteomic studies have shown a greater level of
success, most likely due to the combination of tissue solubilization,
HIAR and proteolytic digestion, which act in concert to extract a much
larger fraction of the proteome than full length protein studies. It is
this success which has led to multiple label-based and label-free quan-
titative studies. The full import of such a bottom-up approach became
apparent when it was shown that PTM containing peptides can be
enriched and characterized in FFPE tissues, and that these PTMs are pre-
served through the ﬁxation process. Spatial proteomics has also been
added to the bottom-up toolbox with peptide MALDI imaging on FFPE
tissue. These studies will have their greatest impact in concert with sur-
gical pathology by combining tissue-speciﬁc peptide distribution data
with histological annotation and patientmeta-data. This has been dem-
onstrated in multiple retrospective studies with hundreds of patients.
The application of the aforementioned developments to tumour
tissue is apparent throughout the literature. As discussed in this review,
top-down studies have mapped signaling networks using proteinicro-array cores containing either adenocarcinoma or squamous cell carcinoma of the lung
ancer, green= non-cancer) of the haematoxylin and eosin stained cores. Panels a–d (right)
om Groseclose et al. Copyright 2008 John Wiley and Sons [103].
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markers using quantitative proteomics and MALDI imaging studies
have mined large tissue cohorts for tumour-speciﬁc markers.
As evidenced by the method developments and applications for
tissue proteomics, FFPE archives are an incredibly valuable resource
and will invariably form a signiﬁcant component of large-scale retro-
spective studies in future.
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